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ABSTRACT 
Carbonic anhydrases (CAs. EC 4.2.1.1) are ubiquitous metalloenzymes that catalyze the 
reversible hydration of carbon dioxide to bicarbonate and proton. In humans, 15 isozymes 
have been described with different subcellular localization. Indeed, CA I-III, VII, and XIII are 
cytosolic, CA IV, IX, XII and XIV are membrane-bound, CA VA and CA VB are 
mitochondrials, and CA VI is secreted. Human CA isozymes are extensively distributed in 
several tissues and organs where, as modulators of pH and ion transport, they take part in a 
variety of physiological and pathological processes. As a result, in the last years many of 
these enzymes have become important therapeutic targets for pharmaceutical research. 
However, given the high degree of sequence and structure similarity among the different 
isoforms, to date most of the CA-directed drugs developed lack of selectivity and 
consequently present many side-effects.  
X-Ray crystallography is one of the most useful instruments in the structure-based drug 
design of selective molecules able to interact with a target enzyme. Indeed, there are several 
examples in the literature where knowledge of the crystallographic structure of an enzyme 
allowed the design of molecules able to interact with specific residues, thus regulating 
enzyme biological activity. This is why in recent years there has been an extensive research 
effort focusing on the crystal structure resolution of all catalytically active -CA isoforms, 
with the result that most of the human CA isoforms have been so far structurally 
characterized.  
As a part of a general research project based on the structure-based drug design of isoform-
selective CA inhibitors (CAIs), my Ph.D thesis has been focused on the study of the 
biochemical and structural features of two cytosolic CA isoforms, namely hCA VII and hCA 
I, which among the 15 human isoforms have been poorly investigated.  
II 
 
hCA VII was the sole cytosolic isozyme, that at the beginning of this Ph.D thesis was not yet 
structurally characterized. This enzyme, similarly to hCA II, is a very efficient catalyst for 
hydration of carbon dioxide, being 10-50 times more active compared to other two cytosolic 
isoforms, hCA I and hCA XIII.
 
However, in contrast to hCA II which is widely spread in 
human tissues, CA VII has a more limited distribution, being localized mainly in some brain 
tissues of humans and rats, in stomach, duodenum, colon, liver and skeletal muscle of mice. 
In the first part of my Ph.D thesis a complete biochemical characterization of this enzyme was 
carried out. Interestingly, these studies highlighted the capability of two reactive cysteines to 
be S-glutathionylated during the purification procedures. Since S-glutathionylation was 
reported in vivo also for another cytosolic CA isozyme, namely CA III, and was associated to 
a protective response to oxidative stress, this phenomenon was investigated in details also for 
CA VII. Such studies showed that Cys183 and Cys217 were involved in adduct formation. 
These reactive cysteines were mutagenized and the corresponding double mutant 
(C183S/C217S) was expressed. The native enzyme, its double mutant and the S-
glutathionylated adduct were fully characterized for their CO2 hydration, esterase and 
phosphatase activity. These kinetic studies indicated that the modification of Cys183 and/or 
Cys217 by glutathione does not have a relevant impact on the active site of the enzyme, 
causing rather small differences in its specific activity. Moreover, an important observation 
was that hCA VII was highly effective as esterase and phosphatase, compared to other 
cytosolic CA isoforms, such as CA I, II, III and XIII. These findings seem to indicate that the 
observed S-glutathionylation, if present in vivo, is not involved in the regulation of the 
enzyme catalytic activity but rather, as observed for hCA III, can help hCA VII to function as 
an oxygen radical scavenger to protect cells from oxidative damage. Further in vivo studies 
are currently underway to investigate this issue. 
III 
 
The X-ray crystallographic structure of a hCA VII mutated form in complex with a classical 
sulfonamide inhibitor, namely acetazolamide, was also solved. A detailed comparison of the 
obtained structure with those already reported for other CA isozymes provided novel insights 
into the catalytic properties of this protein family and offered the basis for a mutagenesis 
approach aimed at determining the contribution of the active site single residues to the 
enzyme catalytic efficiency. Moreover, on the basis of the structural differences detected 
within the active site of the various CA isoforms, further prospects for the design of isozyme-
specific CA inhibitors have been obtained. 
hCA I was one of the first members of the CA family to be identified. Even though the 3D 
structure of this enzyme was first characterized already in 1975, only few structural studies on 
complexes formed with different inhibitors have been reported so far. Since these studies are 
fundamental for the drug design of isoform-selective inhibitors, part of this thesis has been 
dedicated to the structural characterization of a complex that hCA I forms with topiramate 
(TPM), which is a molecule of pharmacological interest for the treatment of epilepsy. The 
analysis of the structure of the complex showed that, upon binding of the inhibitor, the active 
site of hCA I undergoes a profound reorganization, which has never been observed in any 
other CA/inhibitor complex and might therefore be useful in designing CA inhibitors. 
Moreover, the comparison with hCA II/TPM and hCA VA/TPM complex structures, 
previously investigated, showed that a different H-bond network together with the movement 
of active site residues to accommodate the inhibitor may account for the difference of 
inhibition constants of TPM towards different CA isozymes. These data may be helpful in the 
design of CAIs selective for various isozymes.  
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1. Introduction 
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1.1 Carbonic Anhydrases 
Carbonic Anhydrases (CAs. EC 4.2.1.1) are ubiquitous metallo-enzymes, which were firstly 
identified in 1933 in red blood cells of cows (Meldrum and Roughton, 1933). Since then, they 
have been found to be abundant in all mammalian tissues, plants, algae and bacteria. These 
enzymes are encoded by five distinct evolutionarily unrelated gene families (Maren, 1967), 
namely the -, -, -, - and -CAs, which appear to have evolved independently from each 
other, thereby providing an excellent example of convergent evolution. The five CA classes 
have different distributions in the different organisms; in particular, -CAs are present in 
vertebrates, bacteria, algae and chloroplasts, -CAs have been found predominantly in 
bacteria, algae and chloroplasts, -CAs mainly in archaea and some bacteria while -CAs and 
-CAs have been identified only in some marine diatoms (Hewett-Emmett, 2000; Krungkrai 
et al., 2001; Chirica et al., 1997; Smith and Ferry, 2000; Supuran and Scozzafava, 2000; 
2002; Supuran et al., 2003; Roberts et al., 2008; Soto et al., 2006). The members of these 
different classes share very little sequence or structural similarity, but they all require a zinc 
ion in the active site. The only exception is represented by the recently discovered  class that 
can also use a cadmium ion as catalytic metal (Xu et al., 2008; Lane et al., 2005). 
Independently on their source, all CAs catalyze the reversible hydration of carbon dioxide to 
bicarbonate and proton (CO2 + H2O ⇔ HCO3
-
 + H
+
), following a two step catalytic 
mechanism (see Equations 1.1, 1.2 and Figure 1.1). In the first step the nucleophilic attack of 
a zinc-bound hydroxide ion on a carbon dioxide molecule leads to the formation of a 
bicarbonate ion coordinated to Zn(II), which is then displaced by a water molecule (Equation 
1.1). In the second step, which is the rate-limiting one, the basic form of the enzyme, which is 
the catalytically active one, is regenerated by the ionization of the zinc-bound water molecule 
and the transfer of a proton from the active site to the external medium (Equation 1.2) (Figure 
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1.1). This process can be assisted either by active-site residues or by buffers present in 
medium (Supuran et al., 2003; Lindskog and Silverman, 2000; Christianson and Fierke, 1996; 
Bertini et al., 1982).  
EZn
2+
-OH
-
 + CO2⇔EZn
2+
-HCO3
-⇔EZn2+-OH2 + HCO3
-
                        (1.1) 
EZn
2+
-OH2 + B ⇔ EZn
2+
 -OH
-
 + BH
+
                                                     (1.2) 
 
 
Figure 1.1 Schematic representation of the catalytic mechanism for the CA-catalyzed CO2 hydration. 
 
In addition to the carbon dioxide hydration, CAs catalyze a variety of other reactions, such as 
hydration of cyanate to carbamic acid or of cyanamide to urea (Equations 1.3 and 1.4); 
aldehyde hydration to gem-diols (Equation 1.5); hydrolysis of carboxylic or sulfonic acid 
esters (Equations 1.6 and 1.7); as well as other less-investigated hydrolytic processes, such as 
those described by Equations 1.8 to 1.10, even if it is unclear whether these reactions have 
physiological significance (Supuran et al., 2003). 
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O=C=NH + H2O ⇔ H2NCOOH                                 (1.3) 
HN=C=NH + H2O ⇔ H2NCONH2                             (1.4) 
RCHO + H2O ⇔ RCH(OH)2                                       (1.5) 
RCOOAr + H2O ⇔ RCOOH + ArOH                         (1.6) 
RSO3Ar + H2O ⇔ RSO3H + ArOH                             (1.7) 
ArF + H2O ⇔ HF + ArOH                                           (1.8) 
PhCH2OCOCl + H2O ⇔ PhCH2OH + CO2 + HCl          (1.9) 
RSO2Cl + H2O ⇔ RSO3H + HCl                                 (1.10) 
 
1.2 Human isoforms of CA family 
All human CAs (hCAs) belong to the -class; up to now, fifteen different -CA isozymes 
have been identified among which twelve are catalytically active, (CAs I-IV, VA, VB, VI-
VII, IX and XII-XIV) (Hewett-Emmett, 2000; Supuran and Scozzafava, 2000; 2002; 
Supuran et al., 2003), whereas the remaining three isoforms (CA VIII, X and XI), the so 
called carbonic anhydrase-related proteins (CARPs), are devoid of any catalytic activity 
(Tashian et al., 2000), thus their physiological function is still unknown (Table 1.1). 
-CA isozymes widely differ in cellular localization. In particular, among the catalytically 
active isozymes, four are associated to the cellular membrane (CA IV, CA IX, CA XII and 
CA XIV), two are located into the mitochondria (CA VA and CA VB), one is secreted in 
saliva and milk (CA VI) and five are cytosolic (CAs I-III, CA VII and CA XIII) (Supuran, 
2008a) (Table 1.1). These enzymes are extensively distributed in several tissues and organs 
where, as modulators of pH and ion transport, they take part in a variety of physiological and 
pathological processes. As a result, in the last years they have become important therapeutic 
targets for pharmaceutical research (Supuran, 2008a). Table 1.2 reports a brief presentation of 
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the various diseases in which hCAs are involved. Just to give some examples, among the 
cytosolic isoforms hCA I seems to be involved in retinal and cerebral edema, and its 
inhibition may be a valuable tool for fighting these conditions (Gao et al., 2007).
 
hCA II is 
involved in several diseases such as glaucoma, edema, epilepsy and probably altitude sickness 
(Hen et al., 2011; Mincione et al., 2008; Supuran, 2008b; De Simone et al., 2009; Basnyat et 
al. 2003; Swenson and Teppema, 2007). hCA III is involved in the oxidative stress, 
characterizing a lot of inflammatory diseases. However, it is not yet understood whether the 
enzymatic activity of hCA III, or to the Cys residues present on its surface are responsible for 
the antioxidant effects of this protein (Barreiro and Hussain, 2010; Brancaccio et al., 2010; 
Zimmerman et al., 2004). hCA VII has been distinguished for its contributions to epileptiform 
activity together with hCAs II and XIV (Hen et al., 2011; De Simone et al., 2009; Ruusuvuori 
et al., 2004), and hCA XIII seems to be involved in the sperm motility processes (Lehtonen et 
al., 2004) and its inhibition could be used to obtain contraceptive agents.  
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Table 1.1. Subcellular localization, organ/tissue distribution and CO2 hydrase activity of 
the 15 human -CA isozymes (Supuran, 2008a). 
 
 
 
 
 
 
 
 
 Subcellular localization Organ/tissue 
distribution 
Catalytic activity 
(CO2 hydratation) 
hCA I Cytosol Erythrocytes, 
gastrointestinal tract, eye 
Low 
hCA II Cytosol Erythrocytes, eye, 
gastrointestinal tract, 
bone osteoclasts, kidney, 
lung, testis, brain 
High 
hCA III Cytosol Skeletal muscle, 
adipocytes 
Very Low 
hCA IV Membrane-bound Kidney, lung, pancreas, 
brain capillaries, colon, 
heart muscle, eye 
High 
hCA VA Mitochondria Liver Moderate 
 
hCA VB Mitochondria Heart and skeletal 
muscle, pancreas, kidney, 
spinal cord, 
gastrointestinal tract 
High 
hCA VI Secreted into saliva and 
milk 
Salivary and mammary 
glands 
Moderate
 
hCA VII Cytosol Central nervous system High 
hCA VIII Cytosol Central nervous system Acatalytic 
hCA IX Transmembrane Tumours, gastrointestinal 
mucosa 
High 
hCA X Cytosol Central nervous system Acatalytic 
hCA XI Cytosol Central nervous system Acatalytic 
hCA XII Transmembrane Renal, intestinal, 
reproductive epithelia, 
eye, tumours 
High 
hCA XIII Cytosol Kidney, brain, lung, gut, 
reproductive tract 
Low 
hCA XIV Transmembrane Kidney, brain, liver, eye Medium 
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Table 1.2. Diseases in which hCA isoforms are involved. 
CA isoform Disease in which is involved 
hCA I Retinal/cerebral edema (Gao et al., 2007) 
hCA II Glaucoma (Mincione et al., 2008) 
Edema (Supuran, 2008b) 
Epilepsy (Hen et al., 2011; De Simone et al., 2009) 
Altitude sickness (Basnyat et al., 2003; Swenson and 
Teppema, 2007) 
hCA III Oxidative stress (Barreiro and Hussain, 2010; 
Brancaccio et al., 2010; Zimmerman et al., 2004) 
hCA IV Glaucoma (Matsui et al., 1996) 
Retinitis pigmentosa (Datta et al., 2009; Ochrietor et 
al., 2005) 
Stroke (Tang et al., 2006) 
hCA VA/VB Obesity (De Simone et al., 2008; De Simone and 
Supuran, 2007; 2009; Supuran et al., 2008) 
hCA VI Cariogenesis (Nishimori et al., 2007; Kivelä
 
et al., 
1999) 
hCA VII Epilepsy (Hen et al., 2011; De Simone et al., 2009; 
Ruusuvuori et al., 2004) 
hCA VIII Neurodegeneration (Aspatwar et al., 2010)
 
Cancer (Aspatawar et al., 2010) 
hCA IX Cancer (Guler et al., 2010; De Simone and Supuran, 
2010; Pastorekova et al., 2006) 
hCA X Unknown 
hCA XI Unknown 
hCA XII Cancer (Guler et al., 2010; Pastorekova et al., 2006; 
Battke et al., 2011) 
Glaucoma (Liao et al., 2003) 
hCA XIII Sterility (Lehtonen et al., 2004) 
hCA XIV Epilepsy (Hen et al., 2011; Shah et al., 2005) 
Retinopathies (Ogilvie et al., 2007) 
 
 
1.3 Structural features of human -CAs  
To date, the three dimensional structures of several human -CA isoforms have been 
determined (Kannan et al.,1984; Eriksson et al., 1988; Eriksson and Liljas, 1993; Boriack-
Sjodin, et al., 1995; Stams et al., 1996; Whittington  et al., 2001; 2004; Duda et al., 2005; Di 
Fiore et al., 2008; 2010; Alterio et al., 2009a). The analysis of these structures showed that, as 
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expected on the basis of their high sequence homology, these enzymes present a similar 
structure characterized by a central twisted antiparallel -sheet surrounded by helical 
connections and additional -strands. The active site is located at the bottom of a great, 
conical cavity, roughly wide 12 Å and deep 13 Å, which occurs from the protein surface to 
the centre of the molecule. The catalytic zinc ion is located on the bottom of this cavity, being 
tetrahedrally coordinated by three conserved histidine residues (His94, His96 and His119) and 
a water molecule/hydroxide ion (Figure 1.2) (Lindskog, 1997; Håkansson et al., 1992; Stams 
and Christianson, 2000; Christianson and Fierke, 1996). 
 
 
Figure 1.2 Schematic representation of three-dimensional structure of hCA II, which has been chosen as 
representative -CA. The Zn(II) ion (central gray sphere) and its three histidine ligands (His 94, His 96, His 119) 
are shown. Helix and -strand regions are coloured in green and yellow, respectively. 
 
 
The nucleophilicity of the zinc-bound water molecule, necessary to perform the catalytic 
reaction, is enhanced by a network of hydrogen bonds of this molecule with the hydroxyl 
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moiety of Thr199 and with two other water molecules. The first one, also called “deep water”, 
is located in a hydrophobic pocket delimited by the conserved residues Val121, Val143, 
Leu198 and Trp209 (Christianson and Fierke, 1996), that constitute the substrate-binding site 
in isozyme II, while the second one is located in a hydrophilic environment toward the 
entrance of the active site (Figure 1.3) (Supuran et al., 2003; Lindskog and Silverman, 2000; 
Stams and Christianson, 2000).  
 
 
Figure 1.3 Active site of hCA II. The zinc ion is tetrahedrally coordinated by the three catalytic histidines and a 
water molecule/hydroxide ion, which is engaged in well-defined network of hydrogen bonds. 
 
 
The active site cavity of all the hCA isoforms can be considered as roughly divided into two 
very different environments: one delimited by a cluster of hydrophobic amino acids, and the 
other one surrounded with hydrophilic residues (Figure 1.4). These regions have been 
described as very important in assisting the enzyme to perform the catalytic reaction; indeed 
the hydrophobic region plays a key role in sequestering the CO2 substrate, orienting the 
carbon atom for nucleophilic attack by the zinc-bound hydroxide (Domsic et al., 2008; Merz, 
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1991). On the other hand the hydrophilic region is important to create a well ordered solvent 
network, which allows the transfer of the proton from the zinc-bound water molecule to the 
bulk solvent (Figure 1.3), in order to regenerate the active form of the enzyme (Domsic et al., 
2008; Tu et al., 1989; Silverman and McKenna, 2007; Roy and Taraphder, 2007; Fisher et al., 
2007a).
 
 
 
Figure 1.4 Solvent accessible surface of hCA II. Residues delimiting the hydrophobic half  of the active site cleft 
are shown in magenta, while residues delimiting the hydrophilic one are shown in cyan. 
 
 
1.4 Human -CAs as target for rational drug design 
As mentioned in paragraph 1.1, many hCA isozymes represent an attractive goal for the 
design of inhibitors with biomedical applications. Indeed, while initially CA inhibitors (CAIs) 
were mainly used as diuretics, antiglaucoma and antiepileptics (Supuran, 2008a), the more 
recently developed compounds are undergoing clinical investigation as antitumor, antiobesity, 
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anticonvulsants, and antimicrobials/antifungals agents (De Simone et al., 2008; Thiry et 
al.,2008a; 2008b; Winum et al., 2008; Supuran, 2007).
 
A careful analysis of the existing literature on CAIs allowed to classify these molecules in two 
main classes: those that bind the enzyme active site attaching themselves to the catalytic 
metal, and those that are bound in the active site but do not interact directly with the zinc ion. 
Inhibitors belonging to the first class have been studied in more detail and are generally 
characterized by three main structural elements: a zinc-binding group (ZBG), an organic 
scaffold, and one or more “tails”. Several ZBGs have been explored, among which the 
classical sulfonamide moiety and its bioisosteres, the sulfamate and sulfamide groups, 
constitute the main players. A large number of organic scaffolds and tails were also examined 
(Alterio et al., 2009b). 
A major problem in this kind of inhibitors resides in the lack of selectivity that they present 
for the different hCA isoforms. For this reason last years have seen the development of the 
second class of inhibitors, among which phenols (Nair et al., 1994; Davis et al., 2011), 
polyamines (Carta et al., 2010), coumarins/thiocoumarins and the antiepileptic drug 
lacosamide (Maresca et al., 2009; 2010) are the most interesting representatives. These 
molecules generally bind to the active site but do not interact directly with the catalytic zinc 
ion. In particular, phenols and polyamines are anchored to the zinc-coordinated water 
molecule/hydroxide ion, while the coumarins and lacosamide bind at the border of the active 
cavity partially occluding its entrance. This is a very important feature since the active site 
regions which are less conserved among the different isoforms are those at the entrance of the 
cavity. Thus, inhibitors which bind in these regions may have higher probability to show 
better selectivity.  
However, nevertheless a large number of studies performed by several research groups in 
developing CAIs, none of the currently developed molecules shows a real selectivity for a 
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specific isozyme (Supuran, 2008a; Supuran et al., 2004). Thus, developing isozyme-specific 
CA inhibitors is currently a very challenging task, that should be highly beneficial in 
obtaining novel classes of drugs devoid of various undesired side-effects. Some progress in 
this field has been recently recorded, although a lot of work still has to be performed. As an 
example, the three-dimensional structure of some hCA isozymes is still unknown at the 
present. Knowledge of the structural differences between different isozymes should be 
fundamental to highlight subtle diversities in their active sites to be used in optimized rational 
drug design of inhibitors selective for one isoform with respect to another one. It is also 
desirable that interactions of the same inhibitor(s) with all CA isozymes should be 
characterized by X-ray crystallography, as this will indeed allow us to understand all factors 
governing selectivity in the drug design of CAIs. This is at the moment possible to some 
extent only for acetazolamide, a well known CAI, as its crystal structures in complex with CA 
I, II, VA, VII, IX, XII, XIII and XIV were reported (Di Fiore et al., 2009; 2010; Sippel et al., 
2009; Alterio et al., 2009a; Whittington et al., 2004; 2009; Chakravarty and Kannan, 1994; 
Boriack-Sjodin et al., 1995). However, this is a too simple compound for allowing the use of 
these structural data for the drug design of isoform-selective compounds. Indeed, compounds 
with a more sophisticated chemical may afford a deeper insight into phenomena governing 
these intricate processes.  
 
1.5 Aim of the thesis  
On the basis of the above reported considerations, it is clear the interest that several 
international research groups have shown for studies dedicated to the structure-based drug 
design of isoform-selective CA inhibitors. In this context my Ph.D thesis is also included, 
which has been focused on the study of the biochemical and structural features of two 
cytosolic carbonic anhydrase isoforms, namely hCA VII and hCA I.  
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1.5.1 hCA VII 
hCA VII is one of the least investigated and understood cytosolic hCA isoforms. Similar to 
hCA II, hCA VII shows very high efficiency as catalyst for hydration of carbon dioxide, being 
10-50 times more active compared to other two cytosolic isoforms, hCA I and hCA XIII 
(Supuran, 2008a; Hilvo et al., 2008). However, in contrast to hCA II which is widely spread 
in human tissues, CA VII has a more limited distribution, being localized mainly in some 
brain tissues of humans and rats (Hilvo et al., 2008; Güzel et al., 2009; Ruusuvuori et al., 
2004), in stomach, duodenum, colon, liver and skeletal muscle of mice (Bootorabi et al., 
2010). Recently, CA VII has been noted for its contribution in generating neuronal excitation 
(Thiry et al., 2007a), establishing a functionally excitatory GABAergic transmission by 
supplying bicarbonate anions, which can mediate current through channels coupled to 
GABAA receptors (Thiry et al., 2008b). The observation that this activity is suppressed by 
membrane-permeating CA inhibitors corroborates the involvement of CA VII in neuronal 
excitation and seizures (Ruusuvuori et al., 2004; Thiry et al., 2007b). More recently, a role of 
CA VII in the control of neuropathic pain has also been proposed, suggesting that its 
inhibition may constitute a new pharmacologic mechanism in designing drugs useful for the 
treatment of this pathological condition (Asiedu et al., 2010). 
As part of a general research project based on the structure-based drug design of isoform-
selective CA inhibitors, the first part of this Ph.D thesis has been focused on a complete 
characterization of hCA VII. In particular, in chapter 2 an extensive biochemical and catalytic 
characterization of this enzyme is described, while in chapter 3 its 3D structure together with 
the preparation of several site directed mutants with improved catalytic efficiency is reported.  
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1.5.2 hCA I 
hCA I is one of the first member of this enzyme family to be identified (Meldrum and 
Roughton, 1933). It is a cytosolic enzyme mainly localized in erythrocytes, gastrointestinal 
tract and eyes. The physiological function of this enzyme has been for long time unknown, 
even if recent studies from Feeener‟s group (Gao et al., 2007) demonstrated its involvement 
in retinal and cerebral edema, and that its inhibition may be a valuable tool for fighting these 
diseases. Kinetic characterization of the enzyme showed that hCA I is only a medium catalyst 
for the CO2 hydration reaction compared to hCA II and hCA VII (Table 1.1) (Supuran, 
2008a). Even though the 3D structure of this enzyme was firstly characterized in 1975 
(Kannan et al., 1975), only a few structural studies on the complexes that this enzyme can 
form with the different inhibitors have been reported so far. As mentioned above these studies 
are fundamental for the drug design of isoform-selective inhibitors. For these reasons part of 
this thesis has been dedicated to the structural characterization of a complex which hCA I 
form with topiramate (TPM), a molecule of pharmacological interest for the treatment of 
epilepsy. The comparative analysis between the structures of  the hCA I/TPM complex and 
the hCA II/TPM complex allowed to provide useful insights into the molecular bases 
responsible for the recognition protein-inhibitor, thus providing important hints for the design 
of new isoform-specific CA inhibitors. 
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2. Biochemical characterization of  
hCA VII 
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2.1 INTRODUCTION 
hCA VII is a 263 residues protein which shares 50%, 56%, 49% and 52% sequence identity, 
respectively, with human CA I, CA II, CA III and CA XIII (Hewett-Emmett and Tashian, 
1996; Kivelä et al., 2005; Lehtonen et al., 2004; Pastorekova et al., 2004; Parkkila and 
Parkkila, 1996; Tashian et al., 1990; Di Fiore et al., 2008). Although this protein was firstly 
identified and characterized by Montgomery and coworkers more than 20 years ago 
(Montgomery et al.,1991), it is still one of the least investigated and understood CA isoforms. 
It is well established that CA VII is a highly active cytosolic protein with a limited 
distribution, being localized mainly in brain tissues of humans and rats (Güzel et al., 2009; 
Ruusuvuori et al., 2004). Only recently, immunohistochemical studies have revealed the 
presence of CA VII also in the stomach, duodenum, colon, liver and skeletal muscle of mice 
(Bootorabi et al., 2010), indicating that it represents the major form expressed at the protein 
level in these tissues. In particular, this protein achieves significant levels of expression in the 
liver, together with CA VA (Shah et al., 2000) and CA XIV (Parkkila et al., 2002). While it is 
reported that CA VA regulates the metabolic processes involving hepatic ureagenesis and 
gluconeogenesis (Shah et al., 2000), the role of hepatic CA VII and CA XIV is still unclear 
and needs to be further investigated. Thus, in order to deepen our knowledge concerning the 
functional role of  this enzyme, we initiated our studies on hCA VII expressing it in E.coli and 
characterizing it biochemically.   
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Cloning, expression and purification of hCA VII 
The gene encoding full-length human CA VII (Figure 2.1) was cloned in the pGex-4T-3 
expression vector and the recombinant expression of the GST-fused protein was carried out in 
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E. coli BL21(DE3)pLysS strain, following induction with 0.2 mM IPTG, for 16 h at 22 °C. 
The total cell recombinant GST-CA VII protein fraction was analyzed by SDS-PAGE, 
observing a protein band of the expected molecular size (Figure 2.2). 
 
atgaccggcc accacggctg gggctacggc caggacgacg gcccctcgca ttggcacaag 
ctgtatccca ttgcccaggg agatcgccaa tcacccatca atatcatctc cagccaggct 
gtgtactctc ccagcctgca accactggag ctttcctatg aggcctgcat gtccctcagc 
atcaccaaca atggccactc tgtccaggta gacttcaatg acagcgatga ccgaaccgtg 
gtgactgggg gccccctgga agggccctac cgcctcaagc agtttcactt ccactggggc 
aagaagcacg atgtgggttc tgagcacacg gtggacggca agtccttccc cagcgagctg 
catctggttc actggaatgc caagaagtac agcacttttg gggaggcggc ctcagcacct 
gatggcctgg ctgtggttgg tgtttttttg gagacaggag acgagcaccc cagcatgaat 
cgtctgacag atgcgctcta catggtccgg ttcaagggca ccaaagccca gttcagctgc 
ttcaacccca agtgcctcct gcctgccagc cggcactact ggacctaccc gggctctctg 
acgactcccc cactcagtga gagtgtcacc tggattgtgc tccgggagcc catctgcatc 
tctgaaaggc agatggggaa gttccggagc ctgcttttta cctcggagga cgatgagagg 
atccacatgg tgaacaactt ccggccacca cagccactga agggccgcgt ggtaaaggcc 
tccttccggg cc 
Figure 2.1 Nucleotidic sequence of the full length human CA 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 12% SDS-PAGE of GST-CA VII expression in E. Coli. M, Perfect Protein Markers 
15-150 kDa; NI, not- induced cell fraction; FT, total fraction; FS, soluble fraction. 
 
hCA VII-GST from soluble fraction was affinity-purified on GSTrap resin and, following 
removal of the fused GST-tag by thrombin (GE Healthcare) treatment (Figure 2.3), the 
resulting digest was purified on NHS-actived Sepharose 4 F resin (Amersham), preactived 
with 4-Aminomethyl Benzene-Sulfonamide hydrochloride, pAMBS (Sigma). Eluted 
protein was immediately concentrated and loaded on a Superdex 75 (Figure 2.4) and the 
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Size Exclusion Chromatography (SEC) purified fractions were analyzed by SDS-PAGE, 
observing only one protein band of the expected molecular sizes (Figure 2.5). 
 
 
Figure 2.3 SDS-PAGE analysis of protein upon removal of the fused GST-tag. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Chromatographic elution profile of hCA VII obtained by SEC on a S75column. 
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Figure 2.5 SDS-PAGE of SEC purified fractions. 
 
2.2.2 Biochemical characterization of hCA VII 
Secondary structure of hCAVII was investigated by means of CD in the far-UV region 
(Figure 2.6). The spectrum clearly demonstrated that the enzyme exhibits a folded structure, 
showing a large negative band at 214 nm. Estimation of the secondary structure of hCAVII, 
performed on the basis of the CD spectrum, was carried out according to the Variable 
Selection Method (CDSSTR) by using DICHROWEB (Lobley et al., 2002; Johnson, 1985)
 
and showing a content of 42% -helix and 30% -sheet. hCA VII thermal stability was 
assessed by following changes of CD signal at 214 nm in the temperature range of 25-85 °C. 
The Tm value obtained at the midpoint of the thermal denaturation curve was 56.7 °C (Figure 
2.7). The process was irreversible under the conditions used, likely due to cross-linking 
between the free cysteines present within the aminoacidic sequence (Tornatore et al., 2008; 
Del Vecchio et al., 2006).  
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Figure 2.6 Far-UV CD spectrum of hCA VII. 
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Figure 2.7 Thermal denaturation of hCA VII. 
 
hCA VII purity and molecular weight was further characterized by electrospray ionization 
mass spectrometry. Unexpectedly, the LC-ESI-MS spectrum of purified hCA VII (Figure 2.8 
A) showed two major peaks, corresponding to a mass increment of 305 and 610 Da compared 
to the theoretical molecular weight. When the sample was treated with DTT, a single peak 
occurred with an experimental mass identical to the expected theoretical molecular weight of 
30100.8 Da (Figure 2.8 B). The observed mass increments of 305 and 610 Da were thus 
ascribed to the incorporation of one or two molecules of glutathione (GSH), that covalently 
bind to two of the four cysteine residues of hCA VII (Figure 2.9), during elution from the 
glutathione-Sepharose column with a buffer containing 10 mM GSH. In order to identify 
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which of the four cysteines were involved in the formation of the covalent adducts with GSH, 
a protein sample was prepared by digestion with thrombin directly on the column, without the 
elution with GSH. After elution, it was denaturated with 6 M guanidinium chloride and 
alkylated with 4-vinylpyridine. The peptide mixture produced by digestion with trypsin was 
directly analyzed by LC-ESI-MS/MS, with sufficient accuracy to enable unambiguous 
identification of the triptic peptides (Figure 2.10) (Papa et al., 2007; Tornatore et al., 2008).
 
Fragments containing Cys183 or Cys217 showed that both cysteines were completely 
modified having incorporated a molecule of 4-vinylpyridine. On the contrary, fragments 
containing Cys54 and Cys178 were not identified by molecular mass and MS/MS sequencing, 
but were revealed only after DTT incubation. Altogether these data clearly suggested that of 
the four cysteines in hCA VII, Cys183 and Cys217 were those involved in S-
glutathionylation, whereas Cys54 and Cys178 formed an intramolecular disulfide bridge. 
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Figure 2.8 LC-ESI-MS of purified hCA VII. (A) Deconvoluted mass spectrum of purified hCAVII showed the 
presence of two distinct peaks with a mass greater of 305 and 610 (305*2) compared to the expected one 
(theorical mw 30100.8 Da). (B) After treatment with reducing agent DTT these two peaks disappeared, leading 
to a unique peak of 30100.0 Da. 
 
 
GSPNSMTGHHGWGYGQDDGPSHWHKLYPIAQGDRQSPINIISSQAVYSPSLQPLELSYEACMSLSITNNGHSVQV
DFNDSDDRTVVTGGPLEGPYRLKQFHFHWGKKHDVGSEHTVDGKSFPSELHLVHWNAKKYSTFGEAASAPDGLAV
VGVFLETGDEHPSMNRLTDALYMVRFKGTKAQFSCFNPKCLLPASRHYWTYPGSLTTPPLSESVTWIVLREPICI
SERQMGKFRSLLFTSEDDERIHMVNNFRPPQPLKGRVVKASFRA 
 
Figure 2.9 Amminoacidic sequence of hCA VII. Cysteines at positions 54, 178, 183, and 217 (numbering refers 
to hCA I sequence) are highlighted in yellow. The linker sequence is in red. 
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Figure 2.10 Total Ion Current profile of the peptide mixture of hCA VII produced by digestion with trypsin. 
 
2.2.3 Role of hCA VII S-gluthationylation  
Interesting considerations can be done on the observed in vitro S-glutathionylation of Cys183 
and Cys217 in hCA VII. This covalent modification can be ascribed to a partial oxidation of 
cysteines to sulfenic acids or thiol radicals followed by reaction with GSH (Filomeni et al., 
2005) used for eluting the protein from GSTrap column. Therefore, both the high reactivity of 
Cys183 and Cys217 and the high GSH concentration in the experimental conditions were 
likely the origin of such phenomena. 
Interestingly, S-glutathionylation was earlier observed in vivo for another member of the CA 
family, namely rat liver CA III (Chai et al.,1991; Lii et al., 1996; Rokutan et al., 1989). This 
enzyme was shown to be S-glutathionylated at two cysteine residues in positions 183 and 188, 
likely due to the high concentration of GSH in the liver (Mallis et al., 2000). Moreover, 
microarray analysis of skeletal muscle of wild type and CA III-deficient knockout mice 
suggested that CA III, undergoing rapid reversible S-glutathionylation or irreversible 
oxidation in mildly and exhaustively stressed muscle, has a possible role in the glutathione-
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mediated antioxidative system (Zimmerman et al., 2004). These data were also in agreement 
with a paper of Räisänen and coworkers (Räisänen et al., 1999), where a possible role of CA 
III as an oxygen radicals scavenger to protect cells from oxidative damage was proposed.  
Starting from these observations, a comparative analysis between isozymes VII and III was 
carried out. hCA VII and hCA III present several analogies: both are cytosolic enzymes and 
are localized in tissues having a high oxygen consumption rate, such as skeletal muscle, liver 
and brain. Furthermore, sequence alignment of catalytically active cytosolic -CAs shows 
that while hCAs I, II and XIII contain only one cysteine in their sequnce, hCAs III and VII 
incorporate a higher number of such residues (five and four cysteines for hCA III and VII, 
respectively). Worth noting is the finding that one of the glutathionylated cysteines of hCA 
III, namely Cys183, is also conserved in hCA VII (Figure 2.11). 
 
 
Figure 2.11 Sequence alignment of catalytically active cytosolic -CAs. Conserved residues are underlined, 
catalytic histidines, and the two residues involved in the orientation of the substrate, Thr199 and Glu106, are 
indicated with asterisks, whereas the cysteine residues are highlighted in yellow. 
 
All these considerations strongly suggest that the S-gluthathionylation observed in vitro for 
hCA VII could also be present in vivo, as observed for isoform III. Thus, to obtain more 
insight into the role of the covalent modifications of the enzyme, the kinetic parameters for 
the CO2 hydration activity were measured (Table 2.1) for the wild type enzyme purified in the 
absence of GSH (without covalent modifications) and the glutathionylated enzyme (sgCA 
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VII). Analysis of these data, carried out in collaboration with Supuran‟s group at the 
University of Florence, revealed that the kinetic parameters for CO2 hydration activity of hCA 
VII and sgCA VII were the same; thus S-glutathionylation of cysteines does not affect the 
canonical hydrolytic reaction as well as the affinity for acetazolamide (AZM), one of the most 
characterized CA inhibitor. 
 
Table 2.1 Kinetic parameters for the CO2 hydration reaction 
catalysed by cytosolic isozymes I, II, III and VII. 
Isozyme kcat/KM (M
-1
s
-1
) KM (mM) KI (AZM) (nM) 
hCA I 5.0x10
7
 4.0 250 
hCA II 1.5x10
8
 9.3 12 
hCA III 2.5x10
5
 52 240000 
hCA VII 7.2x10
7
 11.0 2.8 
sgCA VII 8.0x10
7
 10.0 2.7 
 
Measurement of the kinetic parameters was also carried out for non-canonical hydrolytic 
reactions catalyzed by some CAs, i.e. esterase and phosphatase activities (Tables 2.2 and 2.3), 
showing that S-glutathionylated enzyme retains the same catalytic activity as the native form. 
Interestingly, both wild type hCA VII and sgCA VII were shown to act as excellent esterases 
compared to hCA I, II and III, with 4-nitrophenyl acetate as substrate (Table 2.2). Thus, such 
data indicate that hCA VII may have another catalytic activity in vivo, in addition to the CO2 
hydrase catalytic activity. Finally, wild type hCA VII and sgCA VII were at least one order of 
magnitude better phosphatases among the cytosolic isoforms reported here (Table 2.3), while 
hCA III was a better phosphatase compared to hCA II, which instead is the best catalyst for 
the CO2 hydration reaction among the cytosolic isozymes. Thus, there is not a clear-cut 
parallelism between the catalytic activities of these isoforms for the various reactions that they 
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catalyze. It is tempting to speculate that hCA VII may act as an esterase/phosphatase in vivo, 
but this hypothesis has yet to be verified and eventual alternative substrates of this enzyme 
determined. 
Table 2.2 Kinetic parameters for the hydrolysis of 4-nitrophenyl 
acetate catalysed by CA isozymes I ,II,III, VII  
Isozyme kcat/KM (M
-1
s
-1
) KM (mM) KI (AZM) (nM) 
hCA I 753  31 3.025  0.014 1210  76 
hCA II 2607  85 30.53  2.10 28  1.1 
hCA III 139  12 1.234  0.013 7840  230 
hCA VII (3.27  0.12) x106 0.75  0.04 357  12 
sgCA VII (2.39  0.10) x106 0.50  0.05 265  9 
 
Table 2.3 Kinetic parameters for the hydrolysis of 4-nitrophenyl 
phosphate catalysed by CA isozymes I, II, III, VII. 
Isozyme kcat/KM (M
-1
s
-1
) KM (mM) KI (AZM) (nM) 
hCA I 65.55  5.20 0.935  0.100 330  14 
hCA II 14.89  0.54 2.195  0.200 63  5 
hCA III 45.32  3.76 1.345  0.160 6500  124 
hCA VII (2.89  0.09) x104 1.43  0.09 3440  39 
sgCA VII (3.04  0.11) x10
4
 0.97  0.05 2520  49 
 
Altogether these data indicate that the observed S-glutathionylation, if present in vivo, is not 
involved in the regulation of the enzyme catalytic activity but rather, as observed for hCA III, 
might help hCA VII to function as an oxygen radical scavenger to protect cells from oxidative 
damage. Indeed, it is worth noticing that in vivo glutathione is abundant, reaching millimolar 
concentration in most cell types, especially in liver (Filomeni et al., 2005; Marì et al., 2009; 
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2010), which would probably trigger the glutathionylation of CA VII (Filomeni et al., 2005). 
In order to assess if S-glutathionylation of hCA VII might occur in vivo as a result of 
oxidative stress conditions, Western Blotting analyses were performed on mice liver tissues 
kindly provided by prof. S. Parkkila of the University of Tampere, Finland. In particular, liver 
tissues were obtained from mice which had been fed with and without iron since iron can 
cause oxidative stress conditions in cells according to the Fenton reaction (Rizzello et al., 
2007). In fact, the rapid electron transfer between Fe
3+
 and Fe
2+
 allows the generation of two 
very short-lived and highly aggressive species, such as  OH˙ and O2 which can lead to cell 
oxidative stress (Scheme 2.1).  
 
 
 
Scheme 2.1. Fenton reaction 
 
For this purpose, two different antibodies were used: anti-CA VII to identify mCA VII, and 
anti-GSH to verify the S-glutathionylation of cysteines. Preliminary analyses were carried out 
in order to define minimal antibody sensitivity towards purified recombinant CAVII, and in 
vitro S-gluthationilated recombinant CAVII. Results are reported in figures 2.12A and 2.12B, 
where it is evident that the two antibodies show different minimal sensitivity, being 100 ng 
for anti-CAVII (Figure 2.12A), and 500 ng for anti-GSH antibody (Figure 2.12B).  
Unfortunately, western blots on liver extracts incubated with anti-CA VII confirmed the 
presence of the protein in all mice samples (Figure 2.13), but not its S-glutathionylation, 
likely due to the low concentration of CA VII modified protein in the analysed tissues. All 
attempts to concentrate CA VII in liver extracts failed thus other experiments are currently 
Fe
2+
 + H2O2 → Fe
3+
 + OH˙ + OH 
Fe
3+
 + O2
 → Fe2+  + O2  
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underway to overcome these technical limitations and check the eventual presence and role of 
CA VII S-glutathionylation in vivo.  
It is worth to be noticed that apart the formation of mixed disulfide bonds which can protect 
protein functionality, high cysteine reactivity might have a different biological role not related 
to S-gluthationylation. This last matter, as well as the detection of an intramolecular disulfide 
bridge between Cys54 and Cys178 reported by our group and subsequently also by Parkkila‟s 
group (Bootorabi et al., 2010), taken into account that hCA VII is a protein living in a 
cytoplasmatic enviroment, is currently under study. 
 
 
 
 
 
 
 
 
Figure 2.12 A and B Western blot incubated with anti-CA VII (A)  and anti-GSH (B)  antibody using different 
amounts of recombinant CA VII and S-gluthationilated recombinant CA VII. 
 
 
 
 
 
Figure 2.13Western blot incubated with anti-CA VII antibody. Lane 1 and 2: male mice liver tissues fed without 
iron; lane 3 and 4: male mice liver tissues fed with iron; lane 5: 200 ng of hCA VII wild type; lane 6 and 7: 
female mice liver tissues fed without iron; lane 8 and 9: male mice liver tissues fed with iron. 
25ng-50ng-100ng-200ng 
 
100ng - 300ng - 500ng 
B 
A 
   1      2         3     4     5     6       7       8       9 
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2.3 MATERIALS AND METHODS 
2.3.1 Expression vector 
pGeX-4T-3 (GE Healthcare) plasmid was chosen as it represents a powerful host-vector 
system for cloning and expression of recombinant proteins in E. Coli. It contains a strong 
promoter from T7 bacteriophage for chemical induction by IPTG and overexpression of 
recombinant proteins, a multiple cloning site (MCS) and a Thrombin protease recognition site 
for cleaving the fusion protein. In particular, this vector has a GST fusion tag (Figure 2.14). 
 
 
Figure 2.14. Map of expression vector pGex-4T-3. 
 
2.3.2 Chemicals 
Reagents used for preparation of buffers were supplied by Sigma Aldrich and the reagents for 
the growth media of E. coli were from Becton-Dickenson. The reagents for polyacrylamide 
gel electrophoresis were supplied by GE Healthcare. Protein molecular weight markers were 
from Novagen. Phusion DNA polymerase was from Finnzymes and Pfu DNA polymerase is a 
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Stratagene product. Restriction enzymes and T4 DNA ligase were from New England 
Biolabs. All molecular biology kits were from Qiagen. Oligonucleotides were synthesized at 
Primm s.r.l. (Milano, Italy); pGex E. coli expression plasmids were from GE Healthcare. 
cDNA of the hCA VII were kindly provided by Prof. Kai Kaila (University of Helsinki, 
Finland). E. coli TOPF‟10 strain, used for cloning, was supplied by Invitrogen; E. coli 
BL21(DE3)pLysS cells, used for overexpression, were supplied by Novagen. PMSF was 
supplied by Sigma-Aldrich. 
 
2.3.3 Cloning of hCA 7 in pGex-4T-3 
The CA7 gene was amplified by PCR from cDNA using Phusion DNA polymerase and the 
following primers: 
Forward 5‟- CGCGCGGAATTCCATGACCGGCCACCACGGCTGG – 3‟ 
                                        EcoRI 
Reverse 5‟-CGCGCGCTCGAGTCATCAGGCCCGGAAGGAGGCCTTTAC – 3‟ 
                                 XhoI 
The forward primer contained the EcoRI restriction site, while the reverse primer was 
designed with the Xho I restriction site plus two stop codons. The amplification reactions were 
performed in a final volume of 50 μL, using 10 ng of template DNA. The reaction mixture 
contained the specific primers (100 pmol each), dNTPs (25 mM each) and the Phusion DNA 
polymerase (2.5 U). PCR was performed using a Biorad apparatus, following the procedure 
indicated below: 
* Initial denaturation (step 1) 1 min at 98 °C  
* Denaturation (step 2) 10 sec at 98 °C  
* Annealing (step 3) 30 sec at 63° C 
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* Elongation (step 4) 30 sec at 72 °C   
for 30 cycles, from step 2.  
* Elongation (step 5) 10 min at 72 °C  
All amplification products were analyzed by 0.8% agarose (Euroclone) gel electrophoresis 
performed in 0.5X TBE buffer (1 mM EDTA, 45 mM Tris base, 45 mM boric acid pH 8.3). 
PCR products were purified by using the QIAquick PCR Purification Kit (Qiagen), and 
digested with Eco RI (20 U/μL) and Xho I (20 U/μL) restriction enzymes. The amplified 
fragment (1μg) was digested with 5 U restriction enzymes for 1 h at 37 ºC in a buffer 
containing 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT pH 7.9 supplemented 
with BSA 100 μg/mL. Following digestion, the fragment was cloned into the corresponding 
sites of the pGex-4T-3 expression vector, downstream from the GST-tag sequence. For this 
purpose, the expression vector was previously digested with the same restriction enzymes (5 
U/μg), and treated with alkaline phosphatase (CIP, 1 U) (NEB) for 15 min at 37 ºC, then for 
45 min at 50 °C. Following digestion, PCR amplifications were purified by QIAquick PCR 
Purification Kit (Qiagen), while the EcoRI/XhoI pGex-4T-3 was purified by QIAquick Gel 
Extraction Kit (Qiagen). For ligation reactions a 1:3 molar ratio (vector/insert DNA) was 
used. Reactions were performed using 20 U/μg DNA of the T4 DNA Ligase (400 U/μL), in a 
final volume of 20 μL, for 3 h at RT. E. coli TOPF‟10 strain was used for cloning. Minipreps 
were performed with Qiaquick miniprep (Qiagen). The identity of the inserts in the resulting 
recombinant plasmids was confirmed by digestion and DNA sequencing (SBM-Zoological Station, 
Napoli).  
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2.3.4 E. coli cell transformation techniques  
2.3.4.1 Preparation of E. coli TOPF’10 cells and transformation by electroporation  
2.5 mL of an overnight culture of E. coli TOPF‟10 cells was inoculated into 250 mL of LB 
medium. The cells were grown up to mid-log phase (0.5 OD at 600 nm) at 37 °C, stored on 
ice for 30 min then harvested by centrifugation (4000 rpm, 15 min, 4 °C). The pellet was 
washed in 125 mL 10% glycerol and recentrifuged. The wash was repeated before 
resuspending in 750 μL 10% glycerol, 0.125% yeast extract, 0.24% tryptone. 
Aliquots of 50 μL cells were mixed with 2 μL of the DNA ligase reaction, incubated for 1 min 
on ice and transferred into chilled plastic cuvettes with an electrode gap of 0.1 cm (BioRad). 
High voltage electroporation (1.8 V) was performed with a Micropulser
TM
 (BioRad) at 50 Hz. 
A shock pulse was applied to competent cells producing pulse length of ~4.0 ms. Immediately 
after electroporation cell mixtures were diluted to 1 mL with LB medium and incubated for 
~1 h shaking at 37 °C. The cells were then plated onto selective solid medium supplemented 
with 100 μg/mL ampicillin and grown 16 h at 37 °C, to isolate the recombinant clones. Single 
clones were inoculated in 5 mL LB medium with the same antibiotic and grown over night 
shaking at 37 °C. Finally, the cells were harvested by centrifugation (13000 rpm, 5 min, 4 °C) 
and processed to extract plasmidic DNA by using the QIAprep Spin Miniprep Kit (Qiagen). 
 
2.3.4.2 Preparation of E. coli BL21(DE3)pLysS competent cells and transformation by 
heat shock  
Single clones of E. coli strains, grown at 37 °C in LB agar, were inoculated into 5 mL LB 
medium and incubated overnight shaking at 37 °C. The cells were inoculated into 400 mL LB 
medium, the culture was grown up to mid-log phase (0.5 OD at 600 nm) at 37 °C, stored on 
ice for 15 min then harvested by centrifugation (4000 rpm, 10 min, 4 °C). The pellet was 
resuspended in 100 mL of 50 mM CaCl2, 10 mM Tris HCl, pH 7.5, stored on ice for 30 min 
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and harvested by centrifugation (4000 rpm, 10 min, 4 °C). The pellet was resuspended in 10 
mL of 50 mM CaCl2, 10 mM Tris HCl, pH 7.5 and 15% glycerol. Aliquots of 200 μL were 
frozen on dry ice and stored at -80 °C. 
Aliquots of 200 μL of competent cells were mixed with 20 ng of plasmidic DNA and stored 
on ice for 30 min. The cell mixtures were transferred at 37 °C for 2 min, on ice for 2 min 
(heat shock) and then diluted to 1 mL with LB medium. An incubation of 1 h shaking at 37 °C 
was performed before plating the cells onto selective solid medium supplemented with the 
appropriate antibiotics (ampicillin, chloramphenicol). 
 
2.3.5 Large-scale expression 
After an initial screening of small-scale expression cultures, performed using different strains, 
temperatures, IPTG concentrations and induction lengths, recombinant constructs were 
transferred into E. coli BL21(DE3)pLysS that assured the best expression level in soluble 
phase. Single clones of E. coli strain, previously transformed with the recombinant expression 
vector and grown at 37 ºC on LB agar containing the appropriate antibiotic, were inoculated 
into 2 mL of LB medium, containing the same antibiotic, and after 2 h were inoculated in 20 
mL prewarmed LB medium. Once at mid-log phase this was in turn inoculated into 400 mL 
of pre-warmed LB medium. Cultures were grown at 37 °C under shaking until they reached 
the mid-log phase (0.7/0.8 OD at 600 nm); then, were induced with 0.2 mM IPTG and growth 
proceeded at 22° over night. The cells were harvested by centrifugation (4000 rpm, 20 min, 4 
°C) and cell pellets were resuspended in a lysis buffer containing PBS 1x, PMSF 1 mM, 
Lysozyme 1 mg/mL, Benzamidine 5 mM and protease inhibitors (Leupeptin 1g/L, 
Pepstatin 1g/L, Aprotinin 1g/L). The suspension was left for 30 min at room 
temperature then sonicated for 12 min, using a Misonix Sonicator 3000 apparatus with a 
micro tip probe and an impulse output of 9/12 Watt. Bacterial lysate was then centrifuged 
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(15000 rpm, 40 min, 4 °C) and the supernatant (soluble fraction) collected and analyzed by 
SDS-PAGE to assess the presence of recombinant products of interest. 
 
2.3.6 Purification of GST-hCA VII 
Lysate containing tagged recombinant protein was purified by affinity chromatography on 1 
mL GSTrap column connected to an AKTA-FPLC system. Before loading the lysate, the 
resin was extensively washed with water then equilibrated in PBS 1x. The lysate was loaded 
into a 10 mL loop at a flow of 0.5 mL/min. Flow-through containing all unbound proteins was 
collected and the resin was washed with PBS 1x; finally GST-tagged protein was eluted with 
10 mL of a solution containing Tris-HCl 30 mM, GSH 10 mM, pH 8.0. All collected pools 
(flow-through, washes and elutions) were analyzed on SDS–PAGE gel and stained with 
Coomassie Brilliant Blue R-250.  
 
2.3.7 Digestion of GST-hCA VII 
2.3.7.1 Thrombin digestion of tagged protein by dialysis 
After purification by affinity chromatography, the GST-tagged protein was dialyzed overnight 
against Thrombin (GE Healthcare) buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0) at 4 °C. 
1 U of Thrombin was added to 200 g of protein substrate. Cleavage product was analyzed by 
polyacrylamide gel electrophoresis. 
 
2.3.7.2 On column thrombin digestion 
1 mL of buffer containing 20 mM Tris-HCl, 150 mM NaCl, pH 8 and thrombin 1 U/200 g of 
protein and the column was sealed and incubated for 16 h at 4 °C. The protein was eluted and 
the cleavage product was analyzed by SDS-PAGE gel. 
35 
 
2.3.8 Affinity chromatography on pAMBS actived resin 
NHS-actived Sepharose 4 Fast Flow (GE Healthcare) was applied to an empty econocolumn 
(BioRad) and washed with 10 c.v. cold 1 mM HCl. The resin was incubated with 1 mL cold 
sodium phosphate 100 mM, pH 7.5 containing 20 mg of 4-Aminomethyl Benzene-
Sulfonamide hydrochloride, pAMBS (Sigma), for 2 h at RT. The resin was repeatedly washed 
with 100 mM sodium acetate solution, pH 4.0 and 0.5 M Tris-HCl, pH 8.0. Finally, the resin 
was equilibrated in 20 mM Tris-HCl, 150 mM NaCl, pH 8.0.  
The thrombin cleaved recombinant protein was loaded on pAMBS resin actived and 
incubated for 30 min at R.T. Flow-through containing all unbound proteins was collected, the 
resin was extensively washed with 20 mM Tris-HCl pH 8.0 and the protein linked to the resin 
was eluted with 500 mM NaClO4, 100 mM NaAc, pH 5.2. Fractions were analyzed by SDS-
PAGE gel and concentrated on Amicon Ultra membranes (Millipore), changing the buffer 
with a solution containing 50 mM Tris-SO4, 150 mM NaCl, pH 8.0. 
 
2.3.9 Size Exclusion Chromatography 
Size exclusion chromatography was performed to purify all recombinant proteins by 
removing aggregates and contaminants. Runs were performed at 0.5 mL/min on a Superdex-
75 10/300 GL (GE Healthcare) column connected to an AKTA Purifier system, in 30 mM 
Tris-HCl pH 8.0, 150 mM NaCl. Molecular weight standards from GE-Healthcare were used 
to calibrate the column. Pools of interest were analyzed by SDS-PAGE gel. 
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2.3.10 Proteins analysis 
2.3.10.1 Determination of protein concentration  
Protein concentration was determined according to the Bradford‟s method (Bradford, 1976). 
The Coomassie Brilliant (Bio-Rad) reagent was added to the samples and the absorbance at 
595 nm was monitored. A solution of bovine serum albumin (BSA) was used as standard. 
Protein concentration was also measured by UV spectroscopy, reading the tryptophan 
absorbance at 280 nm, using a Jasco V-550 UV-VIS spectrophotometer, in a 1 cm quartz cell. 
 
2.3.10.2 Electrophoretic analysis of proteins (SDS-PAGE)  
The electrophoresis on 12% polyacrylamide gel in denaturing conditions was performed 
according to Laemmli‟s protocol (Laemmli, 1970). Samples were denatured at 100 °C for 2 
min in 1% SDS (Applichem), 5% β-mercaptoethanol (Sigma), 0.001% bromophenol blue 
(ICN Biomedicals) and 10% glycerol (Applichem) before loading on a polyacrylamide gel. 
Electrophoresis was performed in 0.025 M Tris-HCl, 0.2 M glycine pH 8.3 and 0.1% SDS, at 
30 mA for ~1 h and proteins were revealed by Coomassie Brilliant-Blue (Applichem) 
staining; the gel was submerged in the staining solution (0.1% Coomassie Brilliant-Blue 
R250, 25% isopropilic alcohol and 10% acetic acid) for 30 min with gentle agitation. The gel 
was washed in a solution containing 30% ethanol and 10% acetic acid to remove the excess of 
Coomassie before drying.  
 
2.3.10.3 Western Blot analysis 
After gel electrophoresis, proteins were transferred to a nitrocellulose membrane (Hybond, 
Amersham Biosciences) in Blotting Buffer (19 mM Tris-HCl pH 8.0, 140 mM Glycine and 
20% methanol) for 90 min, at 100 V, the gel and nitrocellulose membrane being initially 
equilibrated in Blotting Buffer for 15 min. After electro-blotting, the membrane was stained 
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with Ponceau Red to verify protein transfer and incubated in blocking solution (0.5% Milk 
(BioRad) in TBST 1x buffer, containing 500 mM NaCl, 20 mM Tris-HCl pH 7.5, 0.3% 
Tween 20) at room temperature for 1 h.  
To verify the presence of CA VII in mice liver tissues, the membrane was washed with TBST 
1x buffer and then incubated with an anti-CA VII antibody (dilution 1:1000) at 4 °C over 
night (anti-CA VII antibody and mice liver tissues were kindly provided by prof. Seppo 
Parkkila of University of Tampere, Finland). Successively, the membrane was washed with 
TBST 1x buffer and shaked for 1 h at room temperature in 1:5000 diluted horseradish 
peroxidase-conjugated anti-rabbit antibody (BioRad), as the secondary antibody. The 
membrane was finally washed with TBST 1x buffer. In order to verify S-gluthationylation of 
CA VII in mice liver tissues, the membrane was incubated in an anti-GSH antibody (ViroGen, 
Watertown, MA) 1:500 diluition, at 4 °C over night and successively washed with TBST 1x 
buffer and shaked for 1 h at room temperature in 1:5000 diluted horseradish peroxidase-
conjugated anti-mouse antibody (BioRad), as the secondary antibody. 
The detection of immunopositive species by enzyme-linked chemi-luminescence (enhanced 
chemi-luminescence, ECL) was performed according to the manufacturer‟s instructions 
(Super Signal®West Pico Chemiluminescent Substrate, Pierce), using a ChemiDoc XRS 
apparatus (Bio-Rad). 
 
2.3.11 Protein characterization by LC-ESI-MS 
To estimate hCA VII purity and assess its molecular weight, protein analyses were performed 
on a LC-MS system comprising a LCQ DECA XP ion trap mass spectrometer 
(ThermoElectron, Milan, Italy) equipped with an OPTON ESI source (operating at a needle 
voltage of 4.2 kV and 320 °C temperature) and a complete Surveyor HPLC system (including 
MS pump, autosampler and photo diode array [PDA]). For this analysis, 0.5 g of hCA VII 
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was loaded on a Phenomenex Jupiter C4 column (2.0x 250 mm, 300Å) and a linear gradient 
of buffer B (0.05% TFA in CH3CN) in buffer A (0.08% TFA in H2O) from 30% to 70% in 40 
min was used. Mass spectra were recorded continuously in the mass interval 400-2000 amu, 
in 27 positive mode (LC-MS, condition 1). Multicharge spectra were then deconvoluted using 
the BioMass program implemented in the Bioworks 3.1 package provided by the 
manufacturer‟s instruction. Mass calibration was performed automatically by means of 
selected multiple charged ions, in the presence of a calibrant agent (UltraMark; 
ThermoElectron, Milan). All mass values are reported as average. 
 
2.3.12 Redox-state study of hCA VII 
In order to estimate the redox-state of hCA VII, 50 μg of purified protein was denatured in 50 
μL of a solution containing 250 mM Tris-HCl, 1 mM EDTA, and 6 M guanidine chloride pH 
8.5, for 30 min at 45 °C without reducing agents. The protein was then alkylated by 
incubating the sample mix in the presence of 0.12 M 4-vinyl-pyridine (4-VP) at 25°C for 60 
min. The reaction was stopped by cooling the sample at 4 °C. As a control, the protein also 
was reduced, before alkylation by 4-VP. 
Trypsin digestion of wild type hCA VII and its alkylated form, both previously heated at 50 
°C for 30 min, was performed in 50 mM Tris-HCl pH 7.5, choosing a molar ratio trypsin:hCA 
VII of 1:100. The reaction was allowed to proceed at 37 °C for 16 h and the mixture of 
peptides was analyzed by LC-MS, using a BioBasic C18 column (30x2.00 mm ID, 
ThermoElectron) and a method developed with a linear gradient of buffer B in buffer A from 
5% to 70% in 65 min. Mass spectra were recorded continuously at mass intervals of 400-2000 
amu, in positive mode and Data-Dependent Analysis (DDA) in order to fragment the eluted 
peptides and obtain sequence information. 
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2.3.13 CD analysis 
Far-UV circular dichroism spectra of hCA VII were obtained by using a Jasco J-715 
spectropolarimeter, equipped with a PTC-423S/15 Peltier temperature controller, in a 0.1 mm 
quartz cell. Spectra were acquired according the following parameters: far UV range of 190-
260 nm, band width of 2 nm, response of 4 sec, data pitch of 0.1 nm and scanning speed of 20 
nm/min. Spectra were performed at 20 °C, at a protein concentration of 5.5x10
-5
 M in 10 mM 
phosphate buffer pH 8.0. Molar ellipticity per mean residue, [θ] in deg cm2 dmol-1, was 
calculated from the equation: [θ]=[θ]obs·mrw/10·l·C, where [θ]obs is the ellipticity measured in 
degrees, mrw is the mean residue molecular mass, 114 Da, C is the protein concentration in 
gxL
-1
 and l is the optical path length of the cell in cm. Spectra processing was obtained by 
using the Spectra Manager software. 
Thermal denaturation of hCA VII was monitored by using CD spectroscopy. The spectrum 
was recorded using the same Jasco apparatus with a protein sample at the concentration of 
5.5x10
-5
 M in 10 mM phosphate buffer pH 8.0. Specifically, the minimum centered around 
214 nm was monitored as the temperature of the solution was increased from 25 °C to 85 °C 
with a scan rate of 1.0 °C/min. Data were fitted to a two-state transition model, and the 
resulting curve was used to calculate the value of Tm, which corresponds to the temperature 
at the midpoint of the thermal denaturation. 
 
2.3.14 Catalytic activity assays 
All investigations concerning the catalytic activity of wild type hCA VII and sgCA VII were 
carried out in collaboration with Supuran‟s group of the University of Florence, Italy. 
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2.3.14.1 CO2 hydrase activity 
Initial velocities were determined by following the change in absorbance using a stopped-flow 
spectrophotometer (Applied Photophysics Model SX.18MV). CO2 solutions were made by 
bubbling carbon dioxide into water or D2O for the solvent hydrogen isotope effect studies. 
Dilutions were made through two syringes with a gastight connection. The CO2 
concentrations for the substrates ranged from 1.7 to 17 mM in H2O. Maximum absorbance 
was observed at 557 nm, using as buffer-indicator pair 10 mM Hepes, pH 7.4, 0.1 M Na2SO4 
and 0.2 mM phenol red. 
In order to determine the KI, different concentrations of the inhibitor and the enzyme were 
preincubated for 10 min at RT. The kinetic constants were carried out by PRISM 3 software 
(Khalifah, 1971). 
2.3.14.2 Esterase activity assays 
Measurement of the esterase function of wild type hCA VII and sgCA VII was performed 
following the hydrolysis of 4-nitrophenyl acetate and the absorbance change at 405 nm, using 
UV-VIS spectrophotometer (Perkin Elmer Lambda Bio20). The substrate was dissolved in 
acetonitrile and diluted in 10 mM Hepes, 10 mM Tris, pH 7.4, adding 0.1 M Na2SO4. Initial 
velocities were determined at 25 °C and the kinetic constants were carried out by Michaelis-
Menten model at substrate concentrations in the range 0.3-5.0 mM. The uncatalyzed rates 
were subtracted from the observed rates and the values of kcat/KM were determined by PRISM 
software. 
2.3.14.3 Phosphatase activity assays 
This assay was performed following the hydrolysis of 4-nitrophenyl phosphate at 405 nm, 
using UV-VIS spectrophotometer (Perkin Elmer Lambda Bio20) at 25 °C. Substrate 
concentrations varied in the range 0.08-5 mM and the kinetic constants were carried out by 
Michaelis-Menten model, using PRISM software. 
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3. Insights into structural 
determinants responsible of the different 
catalytic efficiency of cytosolic CAs 
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3.1 INTRODUCTION 
Although important advances have recently been reported concerning the catalysis and 
inhibition of human CAs, an important and still unresolved issue in this research field is the 
complete understanding of the structural determinants of the various isozymes contributing to 
the different catalytic efficiency and response to inhibitors. Indeed, kinetic studies on human 
CA isozymes show significant differences in catalytic efficiency. For example among the 
cytosolic isoforms hCA II and hCA VII act as very efficient catalysts, hCA I and hCA XIII 
with medium efficiency, and finally hCA III as a very poor catalyst (Supuran, 2008a; Hilvo et 
al., 2008).
 
Even greater differences have been observed between isozymes when comparing 
the KI values measured for certain clinically used inhibitors. These data are rather surprising 
considering that most of the CA active site residues are highly conserved among the different 
isoforms (Alterio et al., 2009b).  
Much insight regarding the role of different residues on the catalytic mechanism has been 
obtained by mutating residues within the CA active site (Genis et al., 2009; Domsic et al., 
2008; Fisher et al., 2007b; Elder et al., 2004; Elleby et al., 1999; Liang et al., 1993; Fierke et 
al., 1991; Hunt and Fierke, 1997; Taoka et al., 1992; Tu et al., 1989; Almstedt et al., 2009). 
However, most of these mutations have been performed on the ubiquitous, physiologically 
dominant isoform hCA II and to a lesser extent on the slower isoform hCA I. During my Ph.D 
thesis I have continued such studies, focusing my attention on two cytosolic isoforms, hCA 
VII and hCA XIII. In particular, at the beginning of my Ph.D I solved the X-ray structure of 
isoform VII, thus completing the structural characterization of cytosolic human CAs. 
Subsequently, having all the 3D structures of the cytosolic isoforms available, I performed a 
rational design of several hCA VII and hCA XIII mutants, by a detailed structural comparison 
of the active sites of all cytosolic isoforms. The aim of this was to obtain mutated hCA 
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isoforms with improved catalytic efficiency in order to clarify the contribution to the catalytic 
activity of each single residue within the enzyme active site.  
 
3.2 RESULTS AND DISCUSSION 
3.2.1 Structural characterization of hCA VII 
3.2.1.1 Crystallization experiments on native hCA VII 
Several crystallization trials on native hCA VII, produced as described in Chapter 2, were 
carried out using the hanging-drop vapour-diffusion method (Ducruix and Giegè, 1999). The 
search for initial crystallization conditions was performed using Hampton Research Crystal 
Screens I and II (Jancarik & Kim, 1991; Cudney et al., 1994). In particular, an aliquot of hCA 
VII was concentrated to 10 mg/mL in 20 mM Tris-HCl pH 9.0, containing 100 mM NaCl. 
Drops were prepared by mixing 1.0 µL of protein with 1.0 µL of precipitant solution and 
equilibrated against 500 µL of precipitant solution at 20 °C. Analysis of all drops showed the 
formation of several microcrystalline precipitates that, in general, could represent a good 
starting point for searching for the optimal precipitating agent. Several parameters such as 
buffer composition, pH and protein concentration were thus varied to optimize crystallization 
conditions. However, all trials failed since no suitable crystals for X-ray diffraction data grew. 
In order to assess the enzyme stability and homogeneity at the high concentration used for the 
crystallization experiments, the protein sample was analyzed by SDS-PAGE under reducing 
and non-reducing conditions after three days storage at 4 °C. The results of the gel-
electrophoresis showed the presence of covalent oligomers due to the formation of an 
intermolecular disulfide bridge (Figure 3.1). 
44 
 
 
Figure 3.1 12% SDS-Page of hCA VII under non reducing conditions. 
 
Thus, to avoid the crystallization problems caused by the mixture of structurally different 
reduced and oxidized enzyme forms, we expressed a hCA VII mutant, hereafter called hCA 
VII C183S/C217S, where cysteine residues in position 183 and 217, which in the previous 
chapter were demonstrated to be particularly reactive, were mutated into serines (Figure 3.2). 
 
 
 
 
 
 
 
 
 
Figure 3.2 Amminoacidic sequence of hCA VII C183S/C217S (pI 7.0, MW 30068.2 Da). Cysteines 54 and 178 
are shown in red; cysteines 183 and 217 mutated in serines in blue; the linker sequence in brown. 
 
 
3.2.1.2 Production of the hCA VII C183S/C217S mutant 
hCA VII mutations were performed using the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene) and expression of the positive clone was performed in E. Coli BL21(DE3)pLysS, 
following induction with 0.2 mM IPTG, for 16 h at 22 °C. The cell recombinant GST-hCA 
GSPNSMTGHHGWGYGQDDGPSHWHKLYPIAQGDRQSPINIISSQAVYSPSLQPLELS
YEACMSLSITNNGHSVQDFNDSDDRTVVTGGPLEGPYRLKQFHFHWGKKHDVGSEHT
VDGKSFPSELHLVHWNAKKYSTFGEAASAPDGLAVVGVFLETGDEHPSMNRLTDALY
MVRFKGTKAQFSCFNPKSLLPASRHYWTYPGSLTTPPLSESVTWIVLREPISISERQ
MGKFRSLLFTSEDDERIHMVNNFRPPQPLKGRVVKASFRA 
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VII C183S/C217S protein fraction was analyzed by SDS-PAGE, observing a protein band of 
the expected size (Figure 3.3). 
 
 
 
 
 
 
Figure 3.3 12% SDS-PAGE of the expression of GST-CA VII C183S/C217S protein in E. Coli. M, Perfect 
Protein Markers 15-150 kDa; NI, non-induced cell fraction; FT, total fraction; FS, soluble fraction. 
 
The soluble fraction of GST-hCA VII C183S/C217S was affinity-purified on GSTrap resin 
and, following removal of the fused GST-tag by thrombin (GE Healthcare), the resulting 
digest was purified on NHS-actived Sepharose 4 F resin (Amersham) preactived with pAMBS 
(Sigma). Eluted protein was concentrated and loaded on a Superdex 75 (Figure 3.4A) and the 
SEC purified fractions were analyzed by SDS-PAGE, observing a protein band of the 
expected size (Figure 3.4B). 
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Figure 3.4 A) Chromatographic elution profile of hCA VII C183S/C217S obtained by S75 SEC column.  
B) SDS-PAGE of SEC purified fractions. 
 
hCA VII C183S/C217S purity and molecular weight were further characterized by 
electrospray ionization mass spectrometry. The LC-ESI-MS spectrum of the purified enzyme 
showed a single peak with an experimental mass identical to the expected theoretical 
molecular weight of 30068.2 Da (Figure 3.5). 
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Figure 3.5 LC-ESI-MS of purified hCA VII C183S/C217S. 
Deconvoluted mass spectrum showed the presence of a unique peak of 30068.23 Da. 
 
A preliminary characterization of hCA VII C183S/C217S structure was carried out by far-UV 
CD spectroscopy. CD spectra, recorded in the 200-250 nm region, clearly showed that the 
mutated protein exhibited a folded structure. In particular, overlap of the spectra of wild type 
hCA VII and hCA VII C183S/C217S indicated that the mutations cysteine/serine did not 
affect the enzyme secondary structure (Figure 3.6). Thermal stability of the protein was 
investigated by following the CD signal at 214 nm in the temperature range 25-85 °C. The 
Tm value, obtained at the midpoint of the thermal denaturation curve, was 57.0 °C indicating 
that this enzyme had the same stability as the native one (see paragraph 2.2.2). 
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Figure 3.6 Overlap of wild type hCA VII (red line) and hCA VII C183S/C217S (black line) CD spectra. 
 
The kinetic parameters for the CO2 hydration activity of hCA VII C183S/C217S were 
measured in collaboration with Supuran‟s group. Data in Table 3.1 show that the mutation of 
the two cysteines to serines does not significantly affect the CO2 hydration activity and 
affinity for acetazolamide (AZM), a strong inhibitor of CA isozymes (Supuran, 2008a). 
Indeed, the kinetic parameters of hCA VII C183S/C217S were almost identical to those of the 
native enzyme as were their inhibition constants for the inhibitor. Also the ability of hCA VII 
C183S/C217S to act as an esterase and phosphatase was tested and the results compared to 
hCA VII wild type. As is evident from Tables 3.2 and 3.3, the native enzyme and its double 
mutated form show very similar kinetic parameters using 4-nitrophenyl acetate and 4-
nitrophenyl phosphate as substrates. 
 
49 
 
Table 3.1 Kinetic parameters for the CO2 hydration reaction 
Isozyme kcat/KM (M
-1
s
-1
) KM (mM) KI (AZM)(nM) 
hCA VII 7.2x10
7
 11.0 2.8 
hCA VII C183S/C217S 6.5x10
7
 10.8 3.0 
 
Table 3.2 Kinetic parameters for the hydrolysis of 4-nitrophenyl acetate 
Isozyme kcat/KM (M
-1
s
-1
) KM (mM) KI (AZM) (nM) 
hCA VII (3.27  0.12) x106 0.75  0.04 357  12 
hCA VII C183S/C217S (4.20  0.18) x106 1.06  0.08 170  14 
 
Table 3.3 Kinetic parameters for the hydrolysis of 4-nitrophenyl phosphate 
Isozyme kcat/KM (M
-1
s
-1
) KM (mM) KI (AZM) (nM) 
hCA VII (2.89  0.09) x104 1.43  0.09 3440  39 
hCA VII C183S/C217S (3.03  0.11) x104 2.21  0.13 2910  45 
 
3.2.1.3 Crystal structure of hCA VII C183S/C217S 
Crystallization experiments were performed on hCA VII C183S/C217S in its unbound and 
inhibitor-bound form. AZM was used for this purpose. Crystals were only obtained in the 
case of the hCA VII C183S/C217S/AZM complex, using the hanging drop vapour diffusion 
method and PEG 4000 as precipitant. They belonged to the space group P21 with one 
molecule per asymmetric unit, according to a solvent content of 41%. Upon diffraction with 
synchrotron radiation, data were collected to 2.05 Å resolution. The structure was solved by 
molecular replacement using the hCA II structure (Eriksson et al., 1988) as starting model and 
refined with the CNS (Brunger et al., 1998) program. There were no outliers in the 
Ramachandran plot (Laskowski et al., 1993), and all residues were well defined in the 
electron density maps except the for first five N-terminal residues, whose large 
conformational flexibility was also confirmed by high B-factor values. The final model of the 
complex was refined to Rfactor/Rfree values of 0.166/0.207. A full list of refinement statistics 
is reported in Table 3.4. 
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Table 3.4 Summary of refinement statistics 
Refinement Statistics  
Resolution limits (Å)  20.00-2.05 
Number of reflections used in the refinement  15099 
No. of reflections in working set  14352 
No. of reflections in test set  747 
Rfactor/Rfreea 0.166/0.207 
No. of protein atoms  2099 
No. of inhibitor atoms  13 
No. of water molecules 261 
RMSD from ideal values  
Bond lengths (Å)  0.008 
Bond angles (°)  1.5 
Average B-factors (Å
2
)  
Protein, overall 13.9 
Main chains 11.6 
Side chains 14.1 
Solvent and inhibitor atoms 22.3/11.5 
Ramachandran plot statistics  
Residues in the most favored regions (%)  88.2 
Residues in the additionally allowed regions (%)  11.8 
a
 Rfactor= Σhkl Σi ||F0(hkl)|-|FC(hkl)||/Σhkl |F0(hkl), Rfree calculated with 5% of data withheld from refinement. 
 
hCA VII C183S/C217S is a monomeric compact globular protein, whose roughly ovoidal 
shape is approximately 40 x 44 x 40 Å
3
 in size. As already observed for other -CAs (Alterio 
et al., 2009b), its structure consists of a central 10-stranded -sheet surrounded by four -, 
four 310-helices and five additional -strands (Figure 3.7). 
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Figure 3.7 hCA VII C183S/C217S overall fold. -Strands are reported in yellow and helices in red. Disulfide 
bond, zinc ion, catalytic histidine and inhibitor molecule are also shown. 
 
An intramolecular disulfide bond is present in the structure between Cys54 and Cys178. 
However, the observation that these two cysteines are not conserved within the -CA family 
(Alterio et al., 2009b) and that disulfide bonds are extremely rare in cytosolic proteins 
(Kadokura et al., 2003) suggests that this disulfide bond is not present in hCA VII under 
physiological conditions, but instead is an artefact generated by the oxidizing conditions that 
arise during protein handling. Intriguingly, the same intramolecular disulfide bridge was 
recently reported by Parkkila‟s group (Bootorabi et al, 2010) making it appealing to deepen 
our knowledge on the role and function of this protein in its cytosolic environment. Further 
studies are currently under way to clarify this point. 
As observed for other -CA isozymes, the active site is located in a conical cavity about 15 Å 
wide and 15 Å deep, which extends from the surface of the protein to the centre of the 
molecule. The catalytic zinc ion is located at the bottom of this cavity, coordinated by three 
52 
 
histidine residues (Figure 3.7). The fourth coordination position is occupied by the 
deprotonated sulfonamide NH
- 
group of the AZM inhibitor which co-crystallized with the 
enzyme (Figure 3.7). Figure 3.8 shows the main protein–inhibitor interactions. According to 
this figure, the NH
-
 group of the inhibitor is coordinated with the Zn
2+
 ion and is hydrogen 
bonded to the Thr199OG atom (2.80 Å). One oxygen from the sulfonamide moiety accepts a 
hydrogen bond from the Thr199N atom (2.93 Å), while the other one is located 3.07 Å away 
from the catalytic zinc ion. Additional hydrogen bond contacts are established between the 
two N atoms of the 1,3,4,-thiadiazole ring and the hydroxyl group of Thr200, and the O atom 
of the acetamide moiety with the Gln92NE2 atom. A further water-mediated H-bond is 
observed between the N atom of the acetamide group and carbonyl group of Pro201. Several 
other hydrophobic interactions stabilize the inhibitor within the active site cavity. In 
particular, the 1,3,4-thiadiazole ring establishes a number of strong van der Waals interactions 
(distance < 4.5 Å) with residues Gln92, Val121, Leu198 and Val200, while the acetamido 
moiety is stabilized by van der Waals contacts with Gln92, Val121, Phe131 and Leu198. 
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Figure 3.8 The active site of the hCA VII C183S/C217S/AZM complex. Hydrogen bonds, Zn
2+
 coordination and 
residues establishing strong van der Waals interactions with the inhibitor are shown. The simulated annealing 
omit |2Fo-Fc| electron density map, relative to the inhibitor molecule, is reported. 
 
Similarly to that observed for other CA isozymes, the  hCA VII C183S/C217S active site is a 
conical cavity consisting of two distinct portions, one delimited by hydrophobic residues 
(Val121, Phe131, Ala135, Leu141, Val143, Leu198 and Val207) and another delimited by 
hydrophilic ones (Asn62, His64, Gln67, Lys91 and Gln92). Very well defined electron 
density maps were observed for all these residues with the exception of His64, which on the 
contrary was disordered. The high conformational mobility of this residue is likely associated 
with its role as a proton shuttle in catalysis, as already observed for the same residue in other 
-CA isozymes (Fisher et al., 2005). 
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3.2.1.4 Structural comparison with other cytosolic α-CAs 
As previously described, all cytosolic hCAs are characterized by very different kinetic 
features (Supuran, 2008a).
 
Indeed, hCA II and hCA VII are very efficient as catalysts (for 
hCA II kcat/KM = 1.5 x 10
8
 M
-1
 s
-1
 and for hCA VII kcat/KM =8.3 x 10
7
 M
-1
 s
-1
), hCA I and 
hCA XIII are 10–50 times less efficient (for hCA I kcat/KM = 5.0 x 10
7
 M
-1
 s
-1
 and for hCA 
XIII kcat/KM =1.1 x 10
7
 M
-1
 s
-1
), while hCA III is a very poor catalyst (kcat/KM =3.0 x 10
5
 M
-1
 
s
-1
) (Supuran, 2008a; Di Fiore et al., 2008). 
In order to investigate the reasons of the higher catalytic activity of hCA VII and hCA II 
compared to the others cytosolic hCAs, a structural comparison analysis was performed. 
Figure 3.9 shows the structural superposition of all cytosolic isozymes. Analysis of this figure 
reveals that hCA VII has a substantial degree of 3D similarity with all other cytosolic hCAs, 
as expected on the basis of the high sequence identity (hCA VII/hCA I = 50%, hCA VII/hCA 
II = 55%, hCA VII/hCA III = 49% and hCA VII/hCA XIII = 52%). Indeed, the RMSD for the 
superposition of the C atoms of hCA VII C183S/C217S with the corresponding atoms of 
hCA I (Kannan et al., 1984), hCA II (Eriksson et al., 1988), hCA III (Duda et al., 2005) and 
hCA XIII (Di Fiore et al., 2008) was 0.91, 0.55, 0.72 and 0.69 Å, respectively.  
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Figure 3.9 Structural superposition of cytosolic hCAs. hCA I is showed in cyan, hCA II in magenta, hCA III in 
yellow, hCA VII in green and hCA XIII in salmon. 
 
 
 
The main differences among these proteins were observed in the loops connecting b and B, 
C and c, E and D, D and F, and in the C-terminal region. Since these regions are 
located distant to the active site, the observed differences should not have effect on either 
catalytic activity or substrate binding.  
Limiting the comparison to the active site regions, it is possible to observe that most of the 
residues which delimit this cavity are generally conserved either by nature or conformation 
(Figure 3.10). This finding is particularly true when comparing hCA VII to hCA II. Indeed, in 
this case only six substitutions, namely S65A, Q67N, D69E, K91I, A135V, and S204L, are 
observed among the 23 residues which delimit the cavity (Figure 3.11). 
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Figure 3.10 Sequence alignment of all cytosolic -CAs. hCA VII secondary structure elements are shown 
schematically: helices are represented by solid cylinders and -strands as arrows. These regions are named as 
reported by Eriksson et al. (1988), for hCA II. Secondary structure elements not present in the hCA II structure 
are primed. - and 310-helices and strands for hCA I (Kannan et al., 1984), hCA II (Eriksson et al., 1988), 
hCA III (Duda et al., 2005)
 
and hCA XIII (Di Fiore et al., 2005) are highlighted in red and yellow, respectively. 
Conserved residues are underlined, catalytic triad, Thr199 and Glu106 are indicated with black triangles, while 
residues delimiting the active site cavity are marked with asterisks. 
 
 
 
 
Figure 3.11 Active site region of hCA VII with residues which delimit the cavity highlighted in magenta. 
The residues of hCA II active site, which are not conserved in hCA VII, are shown in green. 
 
 
57 
 
3.2.2 Mutagenesis studies on hCA VII: design and preparation of mutants with 
improved catalytic efficiency 
As mentioned above hCA II was the most efficient catalyst of the CA family with a kcat/KM = 
1.5 x 10
8
 M
-1
 s
-1
. hCA VII, even though being a very active enzyme, presented a catalytic 
efficiency nearly half of that of hCA II, with a kcat/KM value of  =8.3 x 10
7
 M
-1
 s
-1
. Structural 
comparison between the two enzymes highlighted six amino acid substitutions between their 
active sites (S65A, Q67N, D69E, K91I, A135V and S204L). Among these residues, four 
(A65, N67, I91 and L204) were previously reported to be important for the catalytic 
efficiency of isoform II. On the basis of these considerations, to clarify the role of different 
residues on the hCA VII catalytic efficiency, four hCA VII mutants, namely S65A, Q67N, 
K91I and S204L, were designed and produced. In each of these mutants, a single amino acid 
of hCA VII was mutated in the corresponding residue present in hCA II. 
Previously reported studies suggested also that the highest catalytic efficiency of hCA II was 
associated with a unique histidine cluster within the enzyme active site, comprised of His3, 
His4, His10, His15, His17 and His64 (Briganti et al., 1997). This cluster extends from the 
interior of the active site to its entrance and, finally, to the surface of the protein (Figure 
3.12A). It has been suggested that this structural motif could be an appropriate „„channel‟‟ for 
efficiently assisting proton transfer from the enzyme active site to the reaction medium 
(Briganti et al., 1997). The importance of this cluster for catalytic efficiency is supported by 
other kinetic/structural studies on hCA I (Lindskog et al., 1991). In this case, the reduced 
catalytic efficiency of hCA I well paralleled with a cluster that was not well defined in the 
enzyme structure, as a result of some histidine substitutions between isozymes I and II and a 
number of additional residues within the active site, namely His67, His200 and His243, 
placed at bifurcating positions and buried enough to only partially assist proton transfer 
(Figure 3.12B). The crystallographic structure of hCA XIII was in line with these 
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observations. Indeed, the lower catalytic efficiency measured for hCA XIII, with respect to 
hCA II and hCA I, corresponded to an isozyme structure where the histidine cluster was not 
present (Figure 3.12C). In fact, apart from His64, no other histidine residue was present in the 
channel connecting the active site to the protein surface. The external residues His10 and 
His15 were placed too distant to ensure a proper proton transfer. Finally the poorest activity 
measured for hCA III was again in agreement with these observations. For this isoform, 
His64, present in all isozymes and acting as the initial proton transfer moiety, was replaced by 
a Lys residue. Also in this case, His10, His15 and His17, confined on the protein surface, 
were non-influent for a proper proton transfer (Figure 3.12D). Structural data here reported on 
hCA VII seems to further confirm the role of the histidine cluster. In fact hCA VII, the most 
active cytosolic hCA after hCA II, presents a well defined histidine cluster, consisting of 
His2, His3 and His64 which connect the interior of the active site to its entrance. However, 
the connection with the protein surface is not well established as in hCA II, as a consequence 
of the lack of His4 and this absence could explain the lower activity with respect to hCA II 
(Figure 3.12E).  
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Figure 3.12 Schematic view of the hCA II (A), hCA I (B), hCA XIII (C), hCA III (D) and hCA VII (E) structures. 
The zinc ion and its three histidine ligands (H94, H96, and H119) are shown. For each isozyme, the histidine 
residues participating to the proton-transfer reaction are also reported as spheres. 
 
 
 
In order to prove this hypothesis the hCA VII double mutant H2S/G4H was also designed and 
produced. So in total five hCA VII mutants were produced. All mutations were carried out on 
the hCA VII C183S/C217S construct; this choice was made because the hCA VII 
C183S/C217S form showed the same biochemical and kinetic parameters as native hCA VII 
being, however, much more stable and homogeneous. The five hCA VII mutants were 
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expressed and purified applying the same protocol as the native enzyme. Correctness of 
sequences was confirmed by DNA sequencing, whereas LC-ESI-MS experiments on purified 
proteins confirmed their integrity and purity. Figures 3.13A and 3.13B report the 
deconvoluted spectra of two out of five purified mutants.  
 
 
 
Figure 3.13 LC-ESI-MS of (A) purified hCA VII H2S/G4H (theorical MW 30098.75 Da) and (B) hCA VII Q67N 
(theorical MW 30054.70 Da). 
 
 
Kinetic parameters of CO2 hydration activity of the five purified mutants were determined in 
collaboration with Supuran‟s group and data obtained are reported in Table 3.5. Results show 
that improvements of the catalytic activity of the mutants were achieved compared to the 
native enzyme, though they did not reach the values of hCA II, whose mutation studies were 
referred to. These results suggest that improvement of the catalytic efficiency of an already 
very active enzyme, such as hCA VII, is probably most evident when only one mutant 
comprehensive of all the mutations identified above is produced. Work is in progress to 
achieve this new construct and verify this hypothesis. 
 
A                                                                            B 
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Table 3.5 Kinetic parameters of hCA VII mutants. 
Enzyme Mutation kcat (s
-1
) KM (mM) 
kcat/KM 
(M
-1
s
-1
) 
KI (AZM) 
(nM) 
hCA VII wt 9.5 × 10
5
 11.4 8.33 × 10
7
 2.5 
hCA VII H2S/G4H 10.8 × 10
5
 11.3 9.55 × 10
7
 2.0 
hCA VII S65A 10.5 × 10
5
 11.3 9.29 × 10
7
 2.5 
hCA VII Q67N 9.7× 10
5
 11.4 8.50 × 10
7
 2.3 
hCA VII K91I 8.4× 10
5
 11.5 7.30 × 10
7
 2.4 
hCA VII S204L 10.3× 10
5
 11.4 9.03 × 10
7
 2.0 
hCA II wt 1.4 × 10
6
 9.3 1.50 × 10
8
 12 
hCA I wt 2.0 × 10
5
 4.0 5.00× 10
7
 250 
 
 
3.2.3 Mutagenesis studies on hCA XIII: design and preparation of mutants with 
improved catalytic efficiency 
The same approach used to design  hCA VII mutants was also applied to hCA XIII. In detail, 
by a structural comparison of hCA XIII and hCA II active sites, five differences among 23 
aminoacids were highlighted in the area close to the substrate binding pocket and to the 
hydrogen-bond network involved into proton transfer, namely: S62N, S65A, R91I, A135V 
and V200T (Figure 3.14). In particular, data reported for hCA II gave evidence of the main 
role that Thr200 and Asn62 have for the proton transfer capacity, as well as Ile91 and Ala65 
due to their vicinity to the substrate binding pocket and their contribution to the hydrogen-
bond network which also facilitates proton transfer (Scolnick and Christianson, 1996; Kockar 
et al., 2010; Mikulski and Silverman, 2010). Thus, four mutants were prepared: hCA XIII 
S62N, hCA XIII S65A, hCA XIII R91I and hCA XIII V200T. In addition, in order to verify 
the hypothesis of the role of the histidine cluster on enzyme efficiency (Briganti et al., 1997), 
we prepared a fifth hCA XIII mutant where Leu3 and Ser4 were mutated into His, obtaining 
the hCA XIII L3H/S4H mutant, where the histidine cluster present in hCA II was reproduced. 
So in total five mutants were designed. In this case site-directed mutagenesis was performed 
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and the mutants of hCA XIII were expressed and purified applying the same protocol as 
described for hCA VII (see paragraphs 2.3.4-2.3.9). Correctness of sequences was confirmed 
by DNA sequencing, whereas LC-ESI-MS experiments on purified proteins confirmed their 
integrity and purity. In figure 3.15 the deconvoluted spectra of four out of five purified 
mutants are shown.  
 
 
 
Figure 3.14 Active site region of hCA XIII with residues which delimit the cavity highlighted in magenta. 
Residues of hCA II active site, which are not conserved in hCA VII, are shown in green. 
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Figure  3.15 Deconvoluted mass spectra of: A) hCA XIII S62N (theorical MW 29614.30 Da); B) hCA XIII S65A 
(theorical MW 29571.28 Da); C) hCA XIII R91I (theorical MW 29544.25 Da); D) hCA XIII V200T (theorical 
MW 29589.25 Da). 
 
Kinetic parameters of CO2 hydration activity of the five purified hCA XIII mutants were 
determined and the data obtained reported in Table 3.6. In this case, improvements of the 
catalytic activity of the hCA XIII mutants were more significant; as an example the V200T 
variant showed a catalytic efficiency double than that of wild type isoenzyme. However, also 
in this case none of the designed mutants was able to reproduce the hCA II catalytic 
efficiency. Again mutants containing more than one aminoacidic substitution should be 
prepared and tested to verify a cumulative effect of these single mutations. 
 
 
 
A                                                                            B 
C                                                                           D 
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Table 3.6 Kinetic parameters of hCA XIII mutants 
Isozyme Mutation 
kcat 
(s
-1
) 
KM 
(mM) 
kcat/KM 
(M
-1
s
-1
) 
KI (AZM) 
(nM) 
hCA XIII wt 1.5 × 10
5
 13.8 1.08 × 10
7
 16 
hCA XIII L3H/S4H 1.8 × 10
5
 13.6 1.32 × 10
7
 11 
hCA XIII S62N 1.4 × 10
5
 10.1 1.40 × 10
7
 105 
hCA XIII S65A 1.6× 10
5
 10.0 1.60 × 10
7
 23 
hCA XIII R91I 1.6× 10
5
 14.5 1.10 × 10
7
 108 
hCA XIII V200T 1.7× 10
5
 9.4 1.80 × 10
7
 13 
hCA II wt 1.4 × 10
6
 9.3 1.5 × 10
8
 12 
hCA I wt 2.0 × 10
5
 4.0 5.0× 10
7
 250 
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3.3 MATERIALS AND METHODS  
3.3.1 hCA7 gene mutagenesis 
Cys183 and Cys217 residues were mutated in serine using the QuikChange Site Directed 
Mutagenesis Kit (Stratagene), for the production of hCA VII C183S/C217S. His2, Gly4, Ser65, 
Gln67, Lys91 and Ser204 residues were also mutated in order to produce the following variants 
of hCA VII: H2S/G4H; S65A; Q67N; K91I and S204L. The primers employed for mutagenesis 
PCR reaction are reported below. 
For C183S: 
FOR  5‟-CTTCAACCCCAAGAGCCTCCTGCCTGCC-3‟ 
REV  5‟-GCAGGCAGGAGGCTCTTGGGGTTGAAG-3‟ 
For C217S: 
FOR  5‟-GAGCCCATCAGCATCTCTGAAAG-3‟ 
REV  5‟-CTTTCAGAGATGCTGATGGGCTC-3‟ 
For H2S: 
FOR  5‟-G ACC GGC TCG CAC GGC TGG GGC -3‟ 
REV  5‟-GCC CCA GCC GTG CGA GCC GGT C-3‟ 
For G4H: 
FOR  5‟-C GGC CAC CAC CAC TGG GGC TAC GGC-3‟ 
REV  5‟- GCC GTA GCC CCA GTG GTG GTG GCC G-3‟ 
For S65A: 
FOR  5'-C AAT GGC CAC GCC GTC CAG GTA G-3‟ 
REV  5‟-C TAC CTG GAC GGC GTG GCC ATT G-3‟ 
For Q67N: 
FOR  5‟-GGC CAC TCT GTC AAT GTA GAC TTC-3‟ 
REV  5‟-GAA GTC TAC ATT GAC AGA GTG GCC-3‟ 
For K91I: 
FOR  5‟-CC TAC CGC CTC ATT CAG TTT CAC TTC-3‟ 
REV  5‟-GAA GTG AAA CTG AAT GAG GCG GTA GG-3‟ 
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For S204L: 
FOR  5‟-CT CCC CCA CTC CTG GAG AGT GTC ACC-3‟ 
REV  5‟-GGT GAC ACT CTC CAG GAG TGG GGG AG-3‟ 
 
The recombinant construct pGex-4T-3/hCA 7 with two reactive cysteines mutated into serines 
was used as template. PCR was performed using Pfu Turbo DNA polymerase enzyme following 
the procedure indicated below:  
 
* Initial denaturation step (step 1) 30 sec at 95 °C  
 
* Denaturation (step 2) 30 sec at 95 °C  
 
* Annealing (step 3) 60 sec at 55 °C  
 
* Elongation (step 4)  6 min at 68 °C  
for 16 cycles from step 2.  
 
Degradation of the methylated, non mutated, parental DNA was carried out by adding Dpn I 
(10 units) to the PCR reaction and incubating for 2 hrs at 37 °C. E. Coli TOPF‟10 was 
transformed with circular nicked obtained dsDNA. The correct insertion of desired mutations 
was confirmed by DNA sequencing. 
 
3.3.2 hCA13 gene mutagenesis 
Lys3, Ser4, Ser62, Ser65, Arg91 and V200 residues were mutated in order to produce the 
variants L3H/S4H, S62N, S65A, R91I and V200T of hCA XIII, and study their catalytic 
activity in comparison with that of hCA II. 
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The sequences of hCA XIII mutants were synthesized by Blue Heron Biotechnology into the 
vector pUCminusMCS, all in frame for cloning in pGex-4T-3 and all containing 5‟ BamHI 
site and 2 STOP codons + XhoI site at 3‟ end. The mutated codons are reported below: 
Leu3/His ⇨ (CTG/CAT)  
Ser4/His ⇨ (AGC/CAT) 
Ser62/Asn ⇨ (AGC/AAC) 
Ser65/Ala ⇨ (AGC/GCG) 
Arg91/Ile ⇨ (CGC/ATT) 
Val200/Thr ⇨ (GTG/ACC) 
The vectors were digested with BamHI (10U/l) and XhoI (20U/l) restriction enzymes and 
cloned in pGex-4T-3 vector as described in paragraph 2.3.3. 
 
3.3.3 Large-scale expression and purification of hCA VII and hCA XIII variants 
The expression and purification of hCA VII C183S/C217S, hCA VII and hCA XIII mutants 
were performed using the same protocols described in paragraphs 2.3.4 to 2.3.9, whereas the 
LC-ESI-MS characterization was carried out as described in paragraph 2.3.11. 
 
3.3.4 hCA VII C183S/C217S/AZM crystallization 
Initial crystallization trials of hCA VII C183S/C217S bound and unbound forms were 
performed at 20 °C using the sparse-matrix sampling method. Screening was carried out using 
commercially available kits (Crystal Screen kits I and II from Hampton Research) and 
performing the trials both by hand and using a Nanodispersion Robotic System, “Microlab 
Starlet Nanojet 8+1” by Hamilton Life Science Robotics. In particular, the hCA VII 
C183S/C217S/AZM complex was prepared by adding a 5-molar excess of inhibitor to a 7 
mg/mL protein solution in 20 mM Tris-HCl, pH 9.0, 100 mM sodium chloride. Thin crystals 
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were only obtained in the presence of the inhibitor from a crystallization conditions 
containing PEG 4000 as precipitant.  
In order to obtain crystals suitable for diffraction data collection a minute optimization of the 
crystallization conditions was performed varying the concentration of precipitant, pH values 
and nature of the buffer. Good results were obtained using a precipitant solution containing 
30% (w/v) PEG 4000, 0.2 M magnesium chloride and 0.1 M Tris-HCl, pH 8.5. Crystals 
appeared in the drops within 2–3 days and grew to a maximum dimension of 0.2x0.15x0.2 
mm
3
 in about 2 weeks (Figure 3.16). The protein-to-reservoir solution ratio was 1:1 in 1 μL 
drops. 
 
Figure 3.16. Crystals of hCA VII C183S/C217S/AZM complex. 
 
3.3.5 Data collection 
X-ray data collection was performed at the ELETTRA synchrotron source (Trieste, Italy) 
using a MAR CCD detector. Prior to data collection, crystals were transferred into a cryo-
protectant solution containing 20% (v/v) glycerol as cryogenic agent, and frozen at 100 K 
under a nitrogen stream produced by an Oxford Cryosystem and maintained at 100 K during the 
data collection. Data were indexed, processed, and scaled with HKL-2000 package 
(Otwinowski and Minor, 1997). Crystal parameters and data collection statistics are reported 
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in Table 3.7. The crystals belong to the space group P21 with one molecule per asymmetric 
unit, according to a solvent content of 41%. 
 
Table 3.7. X-Ray data collection statistics for hCA VII C183S/C217S/AZM complex. 
Space group P21 
Unit cell parameters  
a (Å) 43.78 
b (Å) 66.28 
c (Å) 46.46 
 (°) 113.84 
Resolution limits (Å) 20.00-2.05 
No. of observations 55467 
No. of unique reflections 15321 
Completeness (%) 99.9 (99.1) 
I/σ(I) 26.5 (10.4) 
Average multiplicity 3.6 
R-sym (%)
a
 0.046 (0.094) 
Mosaicity 0.44 
VM (Å
3
Da
-1
) 2.05 
Solvent content (%) 39.9 
a
 R-sym=Σhkl Σi|Ii (hkl)-<I(hkl)>|/Σhkl ΣiIi (hkl), where Ii(hkl) is the ith measurement and 
<I(hkl)> is the weighted mean of all measurements of I(hkl). 
Values in parentheses refer to the highest resolution shell (2.12–2.05 Å). 
 
3.3.6 Structure determination and refinement 
The hCA VII C183S/C217S/AZM crystal structure was solved by molecular replacement 
using the program AMoRe (Navaza, 1994) and the crystallographic structure of hCA II (PDB 
code 1CA2) (Eriksson et al., 1988) as starting model. To avoid bias, water molecules were 
removed from the model. The rotation and translation functions were calculated using data 
between 15.0 and 3.5 Å resolution. The one body translation search, using centred-overlap 
function (c-o), on the first 50 rotation solutions led to a single solution with a correlation 
coefficient of 0.499 and a Rfactor of 0.406. 
Refinement of the structure was performed with CNS (Brunger et al., 1998), and model 
building was performed with O (Jones et al., 1991). Cycles of rigid-body refinement were 
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performed on the model using data between 20.0 and 3.5 Ǻ resolution. At this stage, the 
resulting Rfactor and Rfree were 0.391 and 0.386 respectively. Clear electron density for the 
inhibitor was observed in the difference map after this single round of refinement. 
Introduction of the AZM molecule was followed by several cycles of addition of water 
molecules, manual rebuilding, energy minimization and thermal B-factor refinement, 
reducing the Rfree and Rfactor values to 0.207 and 0.166, respectively. Refinement statistics 
are summarized in Table 3.4. Coordinates and structure factors have been deposited in the 
Brookhaven Protein Data Bank (Accession code 3ML5). 
 
3.3.7 Catalytic activity assays 
All investigations concerning the catalytic activity of the hCA VII C183S/C217S, hCA VII 
and hCA XIII mutants were carried out in collaboration with Supuran‟s group of the 
University of Florence, Italy, as described in paragraph 2.3.14. 
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4. The carbonic anhydrase I-topiramate 
complex 
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4.1 INTRODUCTION 
Obesity is the most frequent metabolic disease in industrialized countries (Friedman, 2003; 
Hill et al., 2003; Ioannides-Demos et al., 2006; Campfield et al.,1998),
 
with more than one 
billion overweight adults worldwide, of which at least 300 million are clinically obese (Cooke 
and Bloom, 2006). Despite its recognition as a healthcare issue, obesity remains largely an 
unsolved medical problem, being a major contributor to the global burden of chronic disease 
and disability. Indeed, obesity is a risk factor for a variety of other diseases such as type 2 
diabetes, cardiovascular diseases and various types of cancer (Van Gaal and Mertens, 1998),
 
and like obesity the prevalence of such obesity-related diseases continues to increase. Thus, 
the development of strategies to reduce the worldwide obesity epidemic has recently become 
an important research goal (Van Gaal and Mertens, 1998; Avenell et al., 2004).
 
Although an 
healthy diet and balanced lifestyle should theoretically help to control the body weight, 
unluckily weight losses achieved with such approaches are quite modest and limited by high 
rates of recidivism and a compensatory slowing of the metabolism (Lau, 2007; Leibel et al., 
1995).
 
Thus, pharmacological interventions for the treatment of obesity are essential to deal 
this problem. Paradoxically, there are very few drugs currently available for the treatment of 
this disease, their mechanism of action is poorly understood and their side effects are rather 
important (Ioannides-Demos et al., 2006). Consequently, the development of new anti-obesity 
agents possessing different mechanisms of action is strongly needed. Fortunately, in last years 
the increased understanding of the physiological mechanisms of body weight regulation has 
allowed to identify new molecular targets, and a wealth of new agents are under active 
development (De Simone et al., 2008). Among the recently suggested approaches to treating 
obesity, it should be mentioned that based on the inhibition of CAs involved in de novo 
lipogenesis, namely hCA VA or/and hCA VB within the mitochondria as well as hCA II 
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within the cytosol (Supuran et al., 2008; De Simone and Supuran, 2007; 2009; De Simone et 
al., 2008).  
Topiramate (TPM, Figure 4.1) (Shank et al., 1994; Edmonds et al., 1996; Stringer, 2000; 
Sabers and Gram, 2000; Bourgeois, 2000; Bialer, 2001) is a sugar sulfamate derivative 
marketed worldwide for the treatment of epilepsy (Lyseng-Williamson and Yang, 2007) and 
prophylaxis of migraine (Ramadan and Buchanan, 2006).
 
However, a growing number of 
other applications (Mirza et al., 2009) of this compound have been recently identified, some 
of which are the treatment of bipolar disorder (Vasudev et al., 2006) and post traumatic stress 
disorder (Berlin, 2007). TPM is also under investigation  for the treatment of several other 
pathologies such as bulimia nervosa (McElroy et al., 2009), obsessive/compulsive disorder 
(Hollander and Dell‟Osso, 2006), idiopathic intracranial hypertension (Celebisoy et al., 
2007), neuropathic pain (Bendaly et al., 2007) and infantile spasms (Zou et al., 2008). 
Obesity is among the pathologies that have been recently explored for treatment with TPM 
(Astrup and Toubro, 2004). In fact, data from studies on TPM performed on several animal 
models have demonstrated that this drug is able to induce weight loss (Richard et al., 2002) 
and have led to clinical trials of TPM for treatment of obesity (Astrup and Toubro, 2004). 
Recently, it was also demonstrated that TPM is a potent in vitro inhibitor of several hCA 
isozymes (Casini et al., 2003) (see Figure 4.1), suggesting that the anti-obesity effects of this 
drug could be ascribed to the inhibition of hCAs VA, VB and II (Supuran et al., 2008; De 
Simone et al., 2008; De Simone and Supuran, 2007; 2009; Chegwidden and Spencer, 1996). 
Indeed, in agreement with these hypotheses, several other studies have demonstrated that 
often the use of CAIs is associated with weight loss (Supuran, 2008a).  
Recently, a comparative structural study on the adducts that TPM forms with hCA VA and 
hCA II has been reported describing the atomic interactions that account for the high affinity 
of TPM for these two enzymes (Casini et al., 2003; Lopez et al., 2009; Vitale et al., 2007). 
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These studies have suggested that TPM could be a promising lead molecule for the design of 
CAIs targeting isozymes involved in lipogenesis, allowing the development of a possible new 
approach for the treatment and prophylaxis of obesity. In this context the study of the 
interactions of TPM with all human CA isoforms represents an important step for the rational 
drug design of selective hCA VA/VB inhibitors to be used as anti-obesity drugs. For these 
reasons, part of this Ph.D thesis has been dedicated to the structural characterization of a 
complex which TPM forms with hCA I. The comparative analysis of such structure with that 
of the hCA II/TPM and hCA VA/TPM complexes allowed us to provide useful insights into 
the molecular bases responsible for recognition of the protein-inhibitor, thus providing 
important hints for the design of new isoform-specific CA inhibitors. 
 
 
Figure 4.1 TPM chemical structure, crystallographic numbering and inhibitory activity against hCA I, II and VA 
are also reported. 
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4.2 RESULTS AND DISCUSSION 
4.2.1 Quality of the model 
The hCA I/TPM complex was crystallized in the space group P212121, with two molecules 
per asymmetric unit (called A and B). The structure was solved by molecular replacement 
using native hCA I (Kannan et al., 1984) as starting model and refined to a crystallographic 
Rfactor of 19.9 % and Rfree of 22.8 % in the 20.00-1.90 Å resolution range (Table 4.1). 
The final model includes 4016 protein atoms and 470 water molecules. The overall quality of 
the model was high, with 87.4 % of the nonglycine residues located in the most favored 
regions of the Ramachandran plot, whereas 12.6 % lies in additional allowed regions (Figure 
4.2). The statistics of refinement are reported in Table 4.1. Poor electron density was observed 
for the first four N-terminal residues of both molecules in the asymmetric unit; thus such 
residues were not included in the final model. The refined structure presented a good 
geometry with RMSD from ideal bond lengths and angles of 0.007 Å and 1.4 °, respectively. 
The average temperature factor (B) for all atoms was 27.0 Å
2
. 
 
Figure 4.2 Ramachandran plot of hCA I/TPM complex. 
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Table 4.1 Summary of refinement statistics 
Refinement Results  
Resolution limits (Å)  20.00-1.90 
Number of reflections used in the refinement  39341 
No. of reflections in working set  37385 
No. of reflections in test set  1956 
Rfactor/Rfree 0.200/0.228 
No. of protein atoms  4016 
No. of inhibitor atoms  44 
No. of water molecules 470 
RMSD from ideal values  
Bond lengths (Å)  0.007 
Bond angles (°)  1.4 
Average B-factors (Å
2
)  
Protein, overall 27.0 
Main chains 24.8 
Side chains 27.1 
Solvent and inhibitor atoms 36.2/27.1 
Ramachandran plot statistics  
Residues in the most favored regions (%)  87.4 
Residues in the additionally allowed regions (%)  12.6 
a
Rfactor= Σhkl Σi ||F0(hkl)|-|FC(hkl)||/Σhkl |F0(hkl)|, Rfree calculated with 5% of data withheld from refinement. 
 
4.2.2 Overall structure 
The two independent molecules in the asymmetric unit overlapped quite well; indeed, the 
superimposition carried out on the backbone positions of all 256 residues led to an RMSD of 
Å. Furthermore, all residues delimiting the active site region adopted an identical 
conformation within the two molecules. Consequently, the following discussion will be 
conducted based on only one arbitrarily chosen molecule, unless otherwise stated.  
Analysis of the structure of the hCA I/TPM complex shows that hCA I is a compact globular 
protein, whose roughly ovoid shape is approximately 47 x 35 x 42 Å
3
 in size. Its structure is 
characterized by a central twisted antiparallel ten-stranded -sheet surrounded by helical 
connections and additional -strands (Figure 4.3) 
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Figure 4.3 hCA I/TPM complex overall fold. -Strands are reported in magenta and -helices in cyan. Zinc ion, 
catalytic histidine and inhibitor molecule are also shown. 
 
 
As observed in the structure of other -CA isozymes, the hCA I active site is located in a 
large conical cavity, which spans from the surface to the center of the protein. The zinc ion is 
located at the bottom of this cavity. Within this cavity a clear electron density for the TPM 
molecule was observed (Figure 4.4).  
The main interactions of the inhibitor with protein are shown in Figure 4.4. The ionized 
nitrogen atom of the sulfamate group of TPM is coordinated to the Zn
2+
 ion, displacing the 
hydroxyl ion/water molecule found in the native enzyme. The zinc coordination sphere is 
completed by the imidazolic nitrogens of His94, His96 and His119. The sulfamate nitrogen is 
also involved in a hydrogen bond with the hydroxyl group of Thr199, while one of the two 
sulfamate oxygens accepts a hydrogen bond from the backbone amide group of the same 
residue. Several other polar interactions are observable between the sugar moiety of the 
inhibitor and the enzyme active site. In particular, TPMO6 and TPMO4 atoms of the 
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inhibitor are hydrogen bonded to His64NE2 and Gln92NE2, respectively (Figure 4.4), while 
TPMO2 and TPMO3 atoms are engaged in a bifurcated hydrogen bond with a water 
molecule, which in turn interacts with the carboxyl group of Pro201. Several other strong van 
der Waals interactions involving residue at distance <4.5 Å (Val62, Ser65, His67, Phe91, 
Leu198, His200 ) contribute to the stabilization of the complex. 
 
 
 
Figure 4.4 Active site region of the hCAI/TPM complex. The simulated annealing omit map, calculated with 
Fourier coefficients |2Fo-Fc|, relative to the inhibitor molecule is shown. Zn
2+
 coordination and hydrogen bonds 
are also shown as dotted lines. 
 
 
4.2.3 Structural comparison with the native enzyme  
A comparison of the hCA I structure in the complex under investigation with the native 
enzyme shows that a significant conformational rearrangement is necessary in the active site 
in order to allow the binding of the inhibitor (Figure 4.5A). Such a rearrangement has never 
before been evidenced in CA–inhibitor adducts, as the active site of this protein is a highly 
rigid one (Alterio et al., 2009b). In particular, in hCA I the residue in position 200 is a bulky 
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histidine residue whereas in all other isoforms a threonine or a valine is present in this 
position (Figure 4.6). As a consequence, the bulky sugar moiety of the TPM molecule cannot 
enter the hCA I active site without a significant displacement of the His200 residue, which in 
turn causes a contemporary movement of residues Trp5 and His67. The movement of His200 
also causes the lost of a hydrogen bond with Pro201 present in the native structure, and the 
consequent formation of a new hydrogen bond with Tyr7.  
 
 
Figure 4.5 (A) Superposition of the 3D structures of hCA I in the native state (blue) (PDB code 2CAB) (Kannan 
et al., 1984) with hCA I in complex with TPM (green). (B) Superposition of the structures of hCA II in the native 
state (magenta) (PDB code 1CA2) (Eriksson et al., 1988) with hCA II in complex with TPM (green) (PDB code 
3HKU) (Casini et al., 2003; Lopez et al., 2009). 
 
 
 
hCA I    1  ASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEIINVGHSFHV  
hCA II   2  -SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNV  
hCA VA   3  --CAWQTSNNTLHPLWTVPVSVPGGTRQSPINIQWRDSVYDPQLKPLRVSYEAASCLYIWNTGYLFQV  
 
hCA I   69  NFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHVAHWNSAKYSSLAEAAS  
hCA II  69  EFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNT-KYGDFGKAVQ  
hCA VA  69  EFDDATEASGISGGPLENHYRLKQFHFHWGAVNEGGSEHTVDGHAYPAELHLVHWNSVKYQNYKEAVV  
                                     * *         *            * 
hCA I  137  KADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFDPSTLLPSSLDFWTYPGSLTHPPLY  
hCA II 137  QPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLL  
hCA VA 137  GENGLAVIGVFLKLGAHHQTLQRLVDILPEIKHKDARAAMRPFDPSTLLPTCWDYWTYAGSLTTPPLT  
                                                                          * 
hCA I  205  ESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVPMQHNNRPTQPLKGRTVRASF---------  
hCA II 205  ECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK--------  
hCA VA 205  ESVTWIIQKEPVEVAPSQLSAFRTLLFSALGEEEKMMVNNYRPLQPLMNRKVWASFQATNEGTRS  
 
Figure 4.6 Sequence alignment of hCA I, hCA II and hCA VA. Strictly conserved residues are highlighted in 
yellow; catalytic histidines, Thr199 and Glu106 are starred, while residues delimiting the active site cavity are 
boxed. 
 
A                                                             B 
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Since residues 5, 67 and 200 present a well conserved conformation within various CA–
inhibitor complexes so far studied (Alterio et al., 2009b; Temperini et al., 2006; 2007; Jude et 
al., 2006; Srivastava et al., 2007; Chakravarty and Kannan, 1994; Kannan, 1981; Kumar et 
al., 1994; Kumar and Kannan, 1994), it is reasonable to hypothesize that their movement 
requires a considerable energy cost. This finding is in agreement with the observation that, 
despite the presence of a large number of polar and hydrophobic interactions between the 
enzyme and the inhibitor, TPM does not show high affinity toward the enzyme with an 
inhibition constant of only 250 nM.  
 
4.2.4 Structural comparison with hCA II/TPM and hCA VA/TPM 
A detailed comparative analysis of the inhibition constants of TPM for the various CAs 
(Figure 4.1) revealed that this molecule binds human isozyme I with an efficiency 25 and 4 
times lower than that measured for hCA II and hCA VA, respectively. To identify the 
molecular features that could be responsible for such behaviour, a detailed structural 
comparison between the adducts that TPM forms with these three isoforms (Casini et al., 
2003; Lopez et al., 2009; Vitale et al., 2007)
 
has been performed. Since hCA I, hCA II and 
hCA VA share a high degree of sequence homology, several hCA I residues involved in TPM 
recognition are also conserved in hCA II and hCA VA (Figure 4.6). Accordingly the 
interactions which TPM established within the three active sites are rather similar (see Figure 
4.7). However, amino acid substitutions at positions 62 and 200 determine important 
differences in inhibitor binding. The main interactions that TPM establishes with residues 
into the active sites of hCA I, hCA II and hCA VA are schematically depicted in Figure 4.7. 
In both cases, as observed for hCA I/TPM (Figures 4.4 and 4.7A) and other CA–sulfamate 
complexes (Alterio et al., 2009b), the TPM sulfamate moiety is tetrahedrally coordinated to 
the zinc ion of the enzyme via its deprotonated nitrogen atom and hydrogen bonded to the 
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Thr199 residue. An extended network of polar interactions between the sugar scaffold of the 
inhibitor and active site protein residues contributes to the stabilization of the complex. It is 
interesting to note that the presence of an additional H-bond interaction in the case of the hCA 
II/TPM complex (Figure 4.7B) could be responsible for the higher affinity of TPM toward 
this isoform (Ki value = 10 nM) with respect to hCA VA (Ki value = 63 nM), even if it does 
not explain such a big difference with hCA I. However, the comparison of the hCA II 
structure in complex with TPM with that of native enzyme reveals that, differently from what 
observed in the case of hCA I, the binding of TPM to hCA II does not cause any significant 
movement of the active site residues (Figure 4.5B). This different behaviour can explain the 
difference in the affinity of TPM toward hCA II and hCA I and further confirms the role of 
the movement of the active site residues in determining the enzyme–inhibitor affinity. Since 
no native structure is available in the case of hCA VA it is not possible to clarify if in this 
case a movement of the active site residues is present or not. 
Altoghter these data suggest that a different H-bond network together with the movement 
of some amino acid residues in order to accommodate the inhibitor are the main players in 
determining the difference of inhibition constants of TPM toward different CA isozymes. 
Thus these data may be helpful in the design of CAIs selective for various isozymes (e.g., 
hCA VA/VB, etc) with potential as anti-obesity drugs or other pharmaceutical 
applications.  
 
 
 
 
 
82 
 
-
NHN
N
NH
N
H
N
N
NH
O
NH
2
N
O
Zn
O
HH
NH
OHO
H
O
S OO
N
O
O
O
OO
2+
Pro201
His64
Gln92
His96
His119
His94
Val62 Ser65
Phe66
His67
Phe91
Leu198
His200
Thr199
2.71
2.90
3.04
3.46
2.88
3.03
2.83
2.00
2.08
2.092.03
    
-
NHN
N
NH
N
H
N
O NH2
N
O
Zn
O
HH
O
NH
2
NH
OH
O
NH
O
O
H
H
O
S OO
N
O
O
O
OO
2+
Pro201
Gln92
His96
His119
His94
His64
Ala65
Phe66
Asn67
Phe131
Leu198
Tyr7
Val121
Thr199
Thr200
Asn62
1.95
1.98
2.05 2.09
2.95
3.23
2.68
3.35
2.94
2.95
2.75
2.95
   
 
 
-
NHN
N
NH
N
H
N
O
NH
2
Zn
NH
OH
O
NH
O
O
H
H
O
S OO
N
O
O
O
O O
2+
Pro201
Gln92
His96
His119
His94
Leu141
Leu198
Val145
Thr199
Thr200
Pro202
Leu65
Gln67
Val121
Tyr131
1.99
2.09
2.18 2.08
3.30
3.00
2.92
2.91
2.94
 
Figure 4.7 Schematic representation of TPM binding within the hCA I (A), hCA II (B) (Casini et al., 2003; 
Lopez et al., 2009) and hCA VA (C) (Vitale et al., 2007) active sites. 
 
A                                                             B 
C 
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4.3 MATERIALS AND METHODS 
4.3.1 hCA I/TPM crystallization and data collection 
hCA I was purchased by Sigma and further purified, as described in paragraph 2.3.8, on NHS-
activated Sepharose 4 FF resin (GE Healthcare) preactivated with pAMBS (Sigma). Eluted 
protein was concentrated to 10 mg ml
-1
 and used for crystallization experiments. 
The hCA I/TPM complex was obtained by adding a 5-molar excess of the inhibitor to a 10 
mg mL
-1
 protein solution in 50 mM Tris-SO4, pH 8.5. Crystals of the complex were obtained 
by the hanging drop vapour diffusion technique at 20° C. Drops were prepared by mixing 1 
L of the hCA I/TPM adduct with 1 L of precipitant solution (30% (w/v) PEG 4000, 0.2 M 
sodium acetate, 0.1 M Tris-HCl, pH 8.5), and equilibrated over a well containing 1 mL of 
precipitant solution. Crystals appeared in the drops after two days and grew in about one week 
to maximum dimensions of 0.2x0.3x0.3 mm
3
 (Figure 4.8). 
 
 
Figure 4.8 Crystal of hCA I/TPM complex. 
 
X-ray diffraction data were collected at 100 K, at the Synchrotron source Elettra in Trieste, 
Italy, using a Mar CCD detector. Prior to cryogenic freezing, the crystals were transferred to 
the precipitant solution with the addition of 15% (v/v) glycerol. The data were processed 
using the HKL2000 package (Otwinowski and Minor, 1997). The crystals belonged to the 
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space group P212121 with unit cell dimension of a = 63.32 Å, b = 71.07 Å, and c = 120.66 Å. 
The Matthews coefficient (VM = 2.4 Å
3
/Da) indicated that the crystallographic asymmetric 
unit contained two molecules according to a solvent content of 48%. Data collection statistics 
are reported in Table 4.2 
 
Table 4.2. X-Ray data collection statistics for hCA I/TPM complex. 
Space group P212121 
Unit cell parameters  
a (Å) 63.32 
b (Å) 71.07 
c (Å) 120.66 
Resolution limits (Å) 20.00-1.90 
No. of observations 220776 
No. of unique reflections 41817 
Completeness (%) 95.7 (74.5) 
I/σ(I) 21.2 (2.3) 
Average multiplicity 5.3 
R-sym (%)
a
 6.7 (33.4) 
Mosaicity 0.24 
VM (Å
3
Da
-1
) 2.4 
Solvent content (%) 47.8 
aRsym=ΣhklΣi |Ii(hkl)-<I(hkl)>|/ΣhklΣi Ii (hkl), where Ii(hkl) is the ith measurement and <I(hkl)> is the 
weighted mean of all measurements of I(hkl). Values in parentheses refer to the highest resolution shell 
(1.97-1.90 Å). 
 
 
4.3.2 Structure determination and refinement 
The hCA I/TPM crystal structure was solved by molecular replacement using the program 
AMoRe (Navaza, 1994)
 
 and the crystallographic structure of native hCA I (PDB code 2CAB) 
(Kannan et al., 1984) as starting model. The rotation and translation functions were calculated 
using data between 15.0 and 3.5 Å resolution. The one-body translation search, using the 
centred-overlap function (c-o), on the first 50 rotation solutions led to a single solution with a 
correlation coefficient of 37.3 % and an Rfactor of 46.9 %. The n-body translation search 
carried out with the phased-translation function (p-t), by including a PC refinement before 
each n-body translation search led to finding the second molecule contained into the 
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asymmetric unit. This improved the correlation coefficient and the Rfactor to 71.3 % and 33.0 
%, respectively. Refinement of the structure was carried out using CNS (Brunger et al., 1998) 
and manual model building was performed with O (Jones et al., 1991). Clear electron density 
for one inhibitor molecule in each active site was observed in the |Fo| - |Fc| maps. Inhibitor 
molecules were gradually built into the model over several rounds of refinement. Restraints 
on inhibitor bond angles and distances were taken from similar structures in the Cambridge 
Structural Database and standard restraints were used on protein bond angles and distances 
throughout refinement. Various cycles of rebuilding and positional and temperature factor 
refinement were necessary to reduce the crystallographic Rfactor and Rfree values (in the 
20.00-1.90 Å resolution range) to 20.0 % and 22.8 %, respectively. The correctness of 
stereochemistry was finally checked using PROCHECK (Laskowski et al., 1993). Refinement 
statistics are summarized in Table 4.1. Coordinates and structure factors have been deposited 
in the Protein Data Bank (accession code 3LXE). 
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5. Conclusions and Perspectives 
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Carbonic anhydrases (CAs) are ubiquitous zinc enzymes present in prokaryotes and 
eukaryotes, all over the phylogenetic tree. These enzymes are efficient catalysts for the 
hydration of carbon dioxide to bicarbonate and protons, playing crucial 
physiological/pathological roles in acid-base homeostasis, secretion of electrolytes, transport 
of ions, biosynthetic reactions, and tumorigenesis. A consistent part of these enzymes are of 
clinical relevance and regarded as drug targets; for this reason, their inhibitors have been 
reported and developed as diuretics, antiglaucoma, anticancer, antiobesity, and antiepileptic 
agents (Supuran, 2007; 2008a). Among the 15 isoforms known in humans one of the least 
investigated when I started my Ph.D thesis was the hCA VII. For years hCA VII has been 
considered as a “brain enzyme” being mainly detected in most of the brain tissues, where it 
contributes to neuronal excitability by providing bicarbonate anion that can mediate current 
through channels coupled to GABAA receptor (Thiry et al., 2008b).
 
Subsequently, hCA VII 
was proposed as acting a role in the control of neuropathic pain, suggesting that its inhibition 
could constitute a new pharmacological mechanism in designing drugs useful for the 
treatment of this pathological condition (Asiedu et al., 2010). Only recently, its presence has 
been detected, by immunohistochemistry, also in other tissues, such as stomach, duodenum, 
colon, liver and skeletal muscle (Bootorabi et al., 2010), indicating that together with hCA 
VA and hCA XIV it represents the major isoform in hepatocytes, even though its function still 
has to be investigated. Apart the above mentioned biological studies, and some 
characterization of hCA VII with developed inhibitors carried out by Supuran‟s group (Güzel 
et al., 2009; Carta et al., 2009),
 
few literature was present on this enzyme; thus, considering 
also that hCA VII is a highly catalytic CA enzyme, second only to hCA II, we started a deep 
biochemical and structural characterization on this enzyme. 
For this purpose, hCA 7 gene was cloned in pGex-4T-3 vector and hCA VII was expressed 
and purified following tag removal. The recombinant protein was obtained with a purity 
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greater than 98% and its analysis by circular dicroism showed a high percentage of -helix 
and -sheet secondary structure, as reported also for the other family hCAs. The analysis 
by LC-ESI-MS/MS highlighted the particular reactivity of two cysteine residues. In 
particular, among the four cysteines present in the aminoacidic sequence, Cys183 and Cys217 
were involved in S-glutathionylation, which occurred during in vitro purification, whereas 
Cys54 and Cys178 were involved in the formation of an intramolecular disulfide bridge. Due 
to the high similarity of hCA VII to hCA III, for which S-glutathionylation was also reported 
in vivo (Supuran, 2008a; Hilvo et al., 2008) and associated to protective response to oxidative 
stress (Zimmerman et al., 2004), we investigated whether this modification observed in vitro 
for hCA VII could be present also in vivo, and if it could affect its catalytic efficiency. To this 
aim, we extensively investigated catalytic activity of this enzyme, looking at the canonical 
catalytic activity, i.e. CO2 hydration, and also at the non-canonical ones, such as esterase, 
phosphatase and sulfatase activities. Obtained data were compared to those achieved with 
native enzyme and with a mutated form where reactive cysteines were mutated in serines 
(C183S/C217S). Results showed that S-glutathionylation does not affect any of the 
investigated catalytic activities of the various forms of the enzyme, which, unexpectedely, 
showed a high degree of phosphatase and esterase activity. Thus, it could be concluded that 
the observed S-glutathionylation, if present in vivo, is not involved in the regulation of the 
enzyme catalytic activity but rather, as already observed for hCA III, could help hCA VII to 
function as an oxygen radical scavenger to protect cells from oxidative damage. Work is still 
in progress to investigate in vivo the eventual hCA VII protective role towards oxidative 
stress. A possible role of hCA VII acting as an esterase and/or phosphatase enzyme is also 
currently investigated as well as eventual alternative substrates are to be determined. 
In order to complete the structural characterization of human cytosolic -CAs, during my 
Ph.D thesis the X-ray structure of isoform VII, which was the last undefined structure, was 
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solved. An important hint for the X-ray study was given by the production of a stable and 
homogenous preparation of the enzyme, achieved by using the C183S/C217S mutated form, 
this avoiding a covalent intermolecular cross-linking of reactive cysteines. As already 
observed for other -CAs (Alterio et al., 2009b), hCA VII structure consists of a central 10-
stranded -sheet surrounded by four - and four 310-helices and five additional -strands. The 
active site is located in a conical cavity about 15 Å wide and 15 Å deep, which extends from 
the surface of the protein to the centre of the molecule. The catalytic zinc ion is located at the 
bottom of this cavity, coordinated by three histidine residues; the fourth coordination position 
is occupied by the deprotonated sulfonamide NH
- 
group of the AZM inhibitor which co-
crystallized with the enzyme. The obtained X-ray structure will be very helpful for the 
rational design of selective hCA VII inhibitors. Work is in progress to this aim.  
Even though cytosolic hCAs share a high sequence identity, they are characterized by very 
different kinetic features; limiting the comparison to the active site regions, it is possible to 
observe that most of the residues which delimit the cavity are generally conserved either by 
nature or conformation. In order to clarify the contribution to the catalytic activity of each 
single residue within the enzyme active site, I performed a rational design on hCA VII and 
hCA XIII enzymes producing in total 10 mutants, where the amminoacid present into their 
catalitic surroundings were replaced by the corresponding aminoacid present in hCA II. 
Results showed that both for hCA VII and hCA XIII improvements were reached even if none 
of the substitution managed to achieve the same hCA II catalytic efficiency.  
Finally, during my Ph.D project, I carried out also the structural characterization of a complex 
which hCA I forms with topiramate (TPM), a clinically used drug for the treatment of 
epilepsy. The analysis of the structure of such complex showed that, upon binding of the 
inhibitor, the active site of hCA I undergoes a profound reorganization, which has never been 
observed in any other CA/inhibitor complex and might therefore be useful in designing CAIs 
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which exploit it. Moreover, the comparison with hCA II/TPM and hCA VA/TPM complex 
structures, previously investigated (Casini et al., 2003; Lopez et al., 2009; Vitale et al., 2007), 
showed that a different H-bond network together with the movement of some active site 
residues in order to accommodate the inhibitor may account for the diverse inhibition 
constants of TPM toward different CA isozymes. These data may be helpful in the design of 
CAIs selective for various isozymes.  
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ABBREVIATION INDEX 
 
4-VP: 4-vinyl-pyridine 
APS: ammonium persulfate 
AZM: acetazolamide 
BSA: albumin from bovine serum 
CA: carbonic anhydrase 
CAI: carbonic anhydrase inhibitor 
CCD: charge-coupled device 
CD: circular dichroism 
dNTP: deoxy nucleotide tri-phosphate 
DTT: dithiothreitol 
ECL: enhanced chemi-luminescence 
EDTA: ethylene-diamino-tetraacetic acid 
ESI: electron spray ionization source 
FPLC: fast protein liquid chromatography 
GSH: reduced glutathione 
GST: Glutathione S-Transferase 
Hepes: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC: high performance liquid chromatography 
IPTG: isopropyl-beta-D-thiogalactopyranoside 
LB: Luria-Bertani broth 
LC-MS: liquid chromatography mass spectrometry 
MCS: multi cloning site 
NHS: N-hydroxysuccinimide 
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OD: Optical Density  
pAMBS: 4-aminomethyl benzene-sulfonamide hydrochloride 
PBS: phosphate buffer saline 
PCR: polymerase chain reaction 
PEG: polyethylene glycol 
PMSF: Phenylmethylsulphonylfluoride (Inhibitor of Serine proteases) 
R.T.: room temperature 
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TBE: Tris Borate EDTA 
TBST: Tris Buffer Salin Tween 20 
Tris: Tris (hydroxy methyl)-amino-methane  
TFA: Trifluoroacetic acid 
Tm: melting temperature 
TPM: topiramate 
ZBG: zinc binding group 
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Abstract 
Human carbonic anhydrase VII (hCA VII) is a cytosolic member of the alpha-CA family. 
This enzyme is mainly localized in a number of brain tissues such as the cortex, hippocampus 
and thalamus and has been noted for its contribution in generating neuronal excitation and 
seizures. Recently, it has been also proposed that hCA VII may be involved in the control of 
neuropathic pain, thus its inhibition may offer a new approach in designing pain killers useful 
for combating neuropathic pain. We report here the X-ray crystallographic structure of a 
mutated form of human CA VII in complex with acetazolamide, a classical sulfonamide 
inhibitor. These crystallographic studies provide important implications for the rational drug 
design of selective CA inhibitors with clinical applications. 
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Abstract 
Topiramate is a widely used antiepileptic drug, which has been demonstrated to act as an 
efficient weight loss agent. Since several studies have pointed out that is a potent in vitro 
inhibitor of several Carbonic anhydrase (CA) isozymes, it has been hypothesized that its anti-
obesity properties could be ascribed to the inhibition of the CAs involved in de novo 
lipogenesis. Consequently, the study of the interactions of with all human CA isoforms 
represents an important step for the rational drug design of selective CA inhibitors to be used 
as anti-obesity drugs. In this paper we report the crystallographic structure of the adduct that 
forms with hCA I, showing for the first time a profound reorganization of the CA active site 
upon binding of the inhibitor. Moreover, a structural comparison with hCA II- and hCA VA- 
adducts, previously investigated, has been performed showing that a different H-bond 
network together with the movement of some amino acid residues in the active site may 
account for the different inhibition constants of toward these three CA isozymes. 
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Abstract 
Human carbonic anhydrase (CA, EC 4.2.1.1) VII is a cytosolic enzyme with high carbon 
dioxide hydration activity. Here we report an unexpected S-glutathionylation of hCA VII 
which has also been observed earlier, in vivo for hCA III, another cytosolic isoform. Cys183 
and Cys217 were found to be the residues involved in reaction with glutathione for hCA VII. 
The two reactive cysteines were then mutated and the corresponding variant (C183S/C217S) 
expressed. The native enzyme, the variant and the S-glutathionylated adduct (sgCA VII) as 
well as hCA III were fully characterized for their CO2 hydration, esterase/phosphatase 
activities, and inhibition with sulfonamides. Our findings suggest that hCA VII could use the 
in vivo S-glutathionylation to function as an oxygen radical scavenger for protecting cells 
from oxidative damage, as the activity and affinity for inhibitors of the modified enzyme are 
similar to those of the wild type one.  
 
 
 
 
 
 
 
